#1Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Q22021 Results Investor presentation 1 Investor Relations | Q2 2021 Results U NOVARTIS | Reimagining Medicine#2Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding our estimates of the impact of past and future COVID-19 related forward purchasing de-stocking on our performance; or regarding the impact of the COVID-19 pandemic on parts of our business including Oncology, generics, and certain geographies; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group's liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics, particularly oncology, in the second half of 2021; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. 2 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#3Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Participants Vas Narasimhan Chief Executive Officer John Tsai Head of Global Drug Development and CMO Harry Kirsch Chief Financial Officer Richard Saynor CEO, Sandoz Marie-France Tschudin President, Novartis Pharmaceuticals Karen Hale Chief Legal Officer Susanne Schaffert President, Novartis Oncology Samir Shah Global Head Investor Relations 3 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#4Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Vas Narasimhan Chief Executive Officer Company overview 4 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#5Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Consistent long-term performance driving confidence for the future Consistent strong performance Sales USD bn, % CAGR CC +6% 22.3 22.9 23.6 25.4 Core Oplnc USD bn, % CAGR CC +13% 6.2 6.9 7.8 8.3 Innovative Medicines Core margin (%), growth cc bps +320bps 34.4 +280bps 36.5 +40bps 36.8 31.8 H1 2018 H1 2019 H1 2020 H1 2021 Confident on growth outlook External expectations based on analyst consensus, as presented at November 2020 Meet Novartis Management1 (USD bn) 47 +4% CAGR 60 60 2019 ACT Growth Drivers Launches Other/Pipeline Sandoz Gx Brands 2025 Consensus IM margin 33.5% 37.6% All growth % in cc. IM - Innovative Medicines division. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 1. Source: Novartis Investor Relations in-house consensus as of November 12, 2020. 5 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#6Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Strong Q2 performance across our value drivers Growth1 Q2 Group sales +9%; H1 +3% Q2 IM sales +10%; H1 +5% Q2 Sandoz sales +5%; H1 -5% Productivity1 1 Innovation References 3 Iptacopan Ph2 studies met endpoints in PNH, IgAN, C3G (IA); Ph3 enrolling 177Lu-PSMA-617 Reduced mortality in patients with mCRPC; received FDA BTD Asciminib KymriahⓇ LeqvioⓇ ZolgensmaⓇ 2 ESG Submitted in US and EU for 3L CML ELARA pivotal study positive final readout in FL enabling submission Resubmitted new drug application to FDA (manufacturing CRL) Showed transformative efficacy in presymptomatic SMA 4 Q2 Group Core operating income +13%; H1 +2% Q2 IM core operating income +14%; H1 +6% Q2 IM core margin 37.3% (+1.3%pts cc); H1 36.8% Delivered 1bn antimalarial courses to patients in need since 1999 Advancing efforts on clinical trial diversity 10-year commitment to address root causes of health disparities All growth % in cc IM - Innovative Medicines division BTD Breakthrough Therapy designation 1. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 6 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#7Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 1 GROWTH Key growth drivers and launches continued momentum in Q2 Q2 key growth driver sales momentum¹ Sales USD Million Entresto 886 Growth vs. PY Growth vs. PY USD Million CC Key growth drivers and launches 306 46% Driving portfolio rejuvenation 51% of IM sales, growing 29% in Q2 sacubitillvalsartan Cosentyx 1,175 231 21% (secukinumab) zolgensma 315 110 48% PROMACTA 513 91 18% (eltrombopag 43% JAKAVI 398 88 19% ruxolitinib AimovigⓇ KesimptaⓇ 51% MayzentⓇ PiqrayⓇ XiidraⓇ LutatheraⓇ KymriahⓇ 33% Xolair 355 66 14% KisqaliⓇ Omalizumab KISQALI 225 66 36% 25% llarisⓇ ribociclib Kesimpta 66 66 nm (ofatumumab) Tafinlar. Mekinist 425 54 ILARIS (canakinumab) 247 47 Xiidra 118 39 69 35 10% 21% 48% 96% ZolgensmaⓇ JakaviⓇ Tafinlar+MekinistⓇ PromactaⓇ EntrestoⓇ MAYZENT. (siponimod) tablets nm not meaningful 1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY Cosentyx® Q2 2018 Q2 2019 Q2 2020 *Includes XolairⓇ, BeovuⓇ, Adakveo®, Luxturna®, TabrectaⓇ, Enerzair, AtecturaⓇ and LeqvioⓇ Q2 2021 Other 7 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#8Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Sandoz business stabilizing in Q2 1 GROWTH 2 PRODUCTIVITY Sandoz performance starting to stabilize (vs. PY, in % cc) Net total sales Q2 2021 +5% H1 2021: -5% Biopharma sales Q2 2021 +5% H1 2021: +6% Core operating income Q2 2021 +3% H1 2021: -19% Challenges remain due to COVID-19 related disruptions Impact on Q2 growth Sales growth excl. PY forward -1% CC purchasing de-stocking1 COVID-19 impact mainly Retail Generics Historically weak cough and cold. season, decreased Anti-Infectives Confidence for future: investments in biosimilars and select Retail generics Biosimilars Pipeline doubled in ~3 years Strategic focus: oncology, immunology, endocrinology, Generics underserved disease areas Strengthening antibiotics manufacturing setup Select investments in complex areas, incl. oncology solids, respiratory, injectables 1. Growth excl. PY forward purchasing de-stocking is a non-IFRS measure; explanation can be found on page 61 of Condensed Interim Financial Report 8 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#9Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 Broad pipeline of novel medicines continued to progress in Q2 Approvals | Cosentyx® US: pediatric PsO Readouts and publications (selected) | EntrestoⓇ China: essential hypertension Submissions | LEQVIO US: resubmission ABL001 asciminib US, EU: chronic myeloid leukemia, 3L US, EU: juvenile idiopathic arthritis | Cosentyx® Designations AAA617 177Lu-PSMA-617 MBG453 sabatolimab FDA Breakthrough Therapy designation in mCRPC FDA Fast Track designation in myelodysplastic syndrome See last slide for all abbreviations 9 Investor Relations | Q2 2021 Results INNOVATION Ph2 - PNH, IgAN, C3G (IA) Ph2 (pivotal) r/r FL (ELARA) Iptacopan KymriahⓇ ZolgensmaⓇ Ph3 - SMA (SPR1NT and STR1VE) Ph3 - PROS (EPIK-P1) Alpelisib Tislelizumab Ph3 - 2L ESCC (RATIONALE 302) BeovuⓇ Ph3nAMD (MERLIN) Positive • Negative NOVARTIS | Reimagining Medicine#10Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Moving forward a breadth of assets to drive long-term growth 3 INNOVATION Selected opportunities, expected 2021 milestones and additional indications Lifecycle management Pharmaceuticals EntrestoⓇ China approval for essential hypertension Iptacopan (LNP023) IgAN, PNH, C3G, aHUS: Ph3 start 2021 Oncology Canakinumab (ACZ885) NSCLC 1L: CANOPY-1 Ph3 readout H2 2021 NSCLC adjuvant iMN HS: SUNRISE, SUNSHINE Ph3 readout H2 2021 177 Lu-PSMA-617 mCRPC 3L: VISION positive readout; submission H2 2021 Cosentyx® L. Planus, jPsA/ERA (submitted), Iscalimab (CFZ533) Sjögren's, kidney Tx, liver Tx GCA, lupus nephritis aBC: MONALEESA-2 OS readout H2 2021 KisqaliⓇ Ligelizumab (QGE031) CSU: PEARL 1, 2 Ph3 readout H2 20211 HR+/HER2- BC (adj) readout 2022 CINDU, food allergy Ph3 start H2 2021 Hyperlipidemia: resubmitted to FDA LeqvioⓇ CVRR-LDLC ZolgensmaⓇ SMA IT Pelacarsen (TQJ230) Branaplam (LMI070) HD: Ph2b start H2 2021 CVRR-Lp(a) TNO155 combinations Tislelizumab (VDT482) Sabatolimab (MBG453) mCRPC pre-taxane, mHSPC: Ph3s started HR-MDS: STIMULUS Ph2 continues blinded after CR readout² AML Solid tumors, multiple combinations being explored in ongoing trials 2L esophageal cancer and NSCLC: submission 2021 'Wild Cards' Asciminib (CML 1L: Ph3 start H2 2021), LNA043 (Osteoarthritis: Ph2b started H1 2021), CSJ117 (Asthma), QBW251 (COPD), LXH254 (BRAF/NRASM melanoma, mRAS/RAF NSCLC), NIS793 (Solid tumors, mPDAC Ph3 start H2 2021) 1. Q4/2021-Q1/2022 potential COVID-19 impact. 2. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial. 10 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#11Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Inclisiran resubmission of NDA filed with FDA- PDUFA action date Jan 1, 2022 ◉ ◉ Own site in Schaftenau (Austria) listed as the manufacturing location for finished product within resubmission Resubmission addresses the FDA Complete Response Letter (CRL) issued in December 2020, stating unresolved facility inspection-related conditions at a third-party manufacturing facility FDA did not raise any concerns related to the efficacy or safety of inclisiran The transfer of the manufacturing of inclisiran (finished product) to the Novartis-owned facility at Schaftenau was planned and initiated in 2020, prior to the receipt of the CRL ◉ Class 2 Resubmission, PDUFA action date Jan 1, 2022 11 Investor Relations | Q2 2021 Results 3 INNOVATION NOVARTIS | Reimagining Medicine#12Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION 177Lu-PSMA-617 reduced risk of death by 38%, and radiographic progression or death by 60% in patients with mCRPC (VISION) Presented at ASCO 2021 OS HR1: 0.62 (95%CI: 0.52, 0.74) Median OS: 15.3 months (14.2, 16.9)³ vs. 11.3 (9.8, 13.5)³ 100 90 80 Event-free probability (%) 288 70 60 50 rPFS HR1: 0.40 (99.2%CI: 0.29, 0.57) Median rPFS: 8.7 months (7.9, 10.8)2 vs. 3.4 (2.4, 4.0)² 100 90 Event-free probability (%) 80 70 60 50 40 30 40 30 20 20 10 177 Lu-PSMA-617+ BSOC (n=551) 10 177 Lu-PSMA-617+ BSOC (n=385) BSOC Only (n=280) BSOC Only (n=196) 0 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 0 1 2 3 4 5 Time from randomization (months) Number still at Risk 177 Lu-PSMA-617 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Time from randomization (months) Number still at Risk 551 535 506 470 425 377 332 289 236 166 112 63 36 15 5 2 0 177 Lu-PSMA-617 + BSOC + BSOC 33 16 6 2 0 0 0 385 373 362 292 272 235 215 194 182 146 137 121 88 83 71 51 49 37 21 18 6 1 1 0 BSOC Only 196 146 119 58 36 26 19 14 14 13 13 11 7 7 7 4 3 3 2 2 0 0 0 0 ◉ ■ ☐ BSOC Only 280 238 203 173 155 133 117 98 73 51 Regulatory submissions in US and EU on track for H2 2021 Data support investigating 177 Lu-PSMA-617 in earlier lines of therapy Two Ph3 studies in pre-taxane 1L/2L mCRPC PSMAfore and mHSPC PSMAddition already underway 1. p<0.001, stratified log-rank test 1-sided. 2.99.2% CI, in line with hypothesis testing strategy. 3. 95% CI. 12 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#13Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION Iptacopan shows clinically meaningful reduction in proteinuria and stabilization of renal function in patients with IgAN and C3G IgAN Primary endpoint data presented at ERA-EDTA 2021 C3G IA data on primary endpoint presented at ASN 2020 EU PRIME designation UPCR (24-hour urine collection) (g/mol) ratio to placebo (of ratio to baseline) 1.2- MCP-mod estimates X MMRM estimates Estimated dose-response curve Pointwise 80% CI 1.0- 0.8- 0.6- 1-sided P=0.038 for dose-response effect 0.4- 0 10 50 100 Iptacopan dose (mg) ■ 23% reduction in proteinuria at 3 months (200mg BID) " Encouraging trend to early stabilization of renal function (eGFR) ■ Well tolerated; no serious infections ■ Ph3 APPLAUSE-IgAN: Ongoing to support iptacopan filings worldwide BID twice daily 200 UPCR 24 h ratio to baseline (80% CI) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 Patient dose escalation: 10mg-100mg b.i.d. during weeks 1-3, followed by 200mg b.i.d. from weeks 4-12 Number of patients with non-missing measurements 12 Baseline Day 28 Time, days 0.51 (0.42, 0.63) One sided p = 0.0005 Day 84 ■ 49% reduction in proteinuria at 3 months ■ Stabilization of renal function (eGFR) at 3 months ■ Well tolerated with no unexpected or new safety findings ■Final Ph2 readout imminent ■ Ph3 APPEAR-C3G: Enrolling, will support filings worldwide MMRM - mixed model repeated measurements UPCR - Urine protein to creatinine ratio CI-confidence interval eGFR - estimated glomerular filtration rate MCP-mod - Multiple Comparison Procedure-Modelling 13 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#14Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Iptacopan reduces LDH and increases hemoglobin in PNH 3 INNOVATION New data (anti-C5 naive) presented at EHA 2021 LDH¹ (U/L) LDH¹ (U/L) 4000- Mean 3000 (90% CI³) 2000 1000 Week 4 Cohort 1: 25. →> 100mg BID Week 12 0 -3 -2 -1 0 1 2 6 8 10 12 14 Week 4000 3000- Mean (90% CI3) 2000- 1000- 0- -2 1.5'ULN ULN4 Week 4 Cohort 2: 50 →>> 200mg BID Week 12 6 10 12 Week 1.5 ULN ULN Hemoglobin (g/L) Hemoglobin (g/L) 170- 150- 130 110- 90 Cohort 1: 25 Week 4 100mg BID Week 12 70- Mean (90% CI) 50- -3 -1 0 4 6 8 10 12 14 Week 170- 150- 130- Week 4 Cohort 21: 50 → 200mg BID 110- Mean (90% C14) 90- 70- Week 12 50- -2 -1 0 1 2 6 8 10 12 14 Week Male LLN Female LLN Male LLN Female LLN FDA Breakthrough Therapy designation ■ ■ New data (EHA 2021) shows clinically important benefits of monotherapy iptacopan in anti-C5 treatment naive PNH patients Previous Ph2 shows iptacopan provided clinical benefits as add-on to eculizumab in PNH residual hemolysis (EBMT 2020) Ph3 APPLY-PNH study to assess superiority of iptacopan vs. anti-C5 therapy ongoing, will support filings worldwide LDH Lactate dehydrogenase raising Hb from 71 to 110 g/L. BID - Twice a day CI - Confidence interval ULN - Upper limit of normal 1. One patient in Cohort 2 was excluded for Hb analyses due to RBC transfusion that occurred between screening and baseline, Source: Jang JH, et al. Iptacopan Effectively Controls Intra- And Extravascular Hemolysis And Leads To Durable Hemoglobin Increase In Patients With Treatment-Naïve PNH. 14 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#15Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION ZolgensmaⓇ SPR1NT data (2-copy cohort) demonstrate transformative, age-appropriate development when used presymptomatically n=14 (2 copy cohort) Achieved CHOP INTEND¹ score ≥58 points 100% 100% CHOP INTEND scores IN WA Ug 10 30 20 50 40 60 0 0 100% Untreated natural history² 79% 15 20 20 5 10 Age (months) Mean age at dosing: 20.6 days (8-34 days); No serious, treatment-related adverse events Presented at EAN 2021 Met primary endpoint: Sitting independently for ≥30 seconds³ Nearly all patients (11/14) within the WHO window for normal development Met secondary endpoint: Survival without permanent ventilation4 Standing alone for ≥3 seconds (Bayley) Most (7/11) within WHO window 64% Walking alone (Bayley) Majority (5/9) within WHO window Data reinforces ZolgensmaⓇ as foundational therapy for both presymptomatic and symptomatic children with SMA 1. CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders. 2. Natural history data from NeuroNEXT prospective natural history study in SMA infants with two copies of SMN2. 3. Functional independent sitting for ≥30 seconds (Bayley-III item #26) at any visit up to 18 months of age. 4. Survival at age 14 months. 15 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#16Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION Sabatolimab: STIMULUS program progressing in MDS and AML MDS 2019 AML STIMULUS MDS-1 Phase 2 HMA combination, enrollment complete 2020 CR Readout PFS Readout (-2022-2023) STIMULUS MDS-2 Phase 3 HMA combination OS Readout (-2023) 2021 STIMULUS AML-1 Phase 2 HMA + venetoclax combination Unfit AML 2022 2023 CR Readout (-2023) Ph1 sabatolimab + HMA data showed promising and durable response rates (58% ORR in MDS1) STIMULUS MDS-1: Ph2 randomized, double-blind, 2 primary endpoints: CR, PFS In June 2021, the DMC determined that the study should continue blinded until PFS readout (event-driven) STIMULUS MDS-2: Ph3 randomized, double-blind, primary endpoint: OS (event-driven) Enrollment ahead of target ■ Parallel execution of trials offers a range of filing options between 2022 and 2023 depending on PFS and/or OS outcomes STIMULUS program has expanded with additional trials in AML and MDS including low-risk MDS AML - Acute Myeloid Leukemia 1. Wei A et al., EHA, June 2021. MDS Myelodysplastic Syndrome CR Complete Remission PFS Progression-free Survival ORR Overall response rate OS Overall Survival DMC - Data Monitoring Committee 16 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#17Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 4 ESG Strong progress on ESG in Q2, with focus on new health equity initiatives and advancing our Global Health efforts Leading on health equity > New target on clinical trial diversity Embedding diversity & inclusion in 100% of Ph3 studies with US participation > Pledged 10-year commitment1 USD 20m to empower 1200 African American students, USD 13.7m to establish research centers > Addressing unmet need in breast cancer Multiyear commitment to address racial disparities in breast cancer: estimated at USD 93bn in excess medical care costs in US Advancing our patient reach > Malaria milestone 1bn courses of antimalarial treatment delivered since 1999 > Accelerate use of digital technologies for global health First use case for dengue which affects 400m cases / year Developing disease surveillance solution with HP Enterprises 1. Via the Novartis US Foundation in collaboration with Historically Black Colleges, Universities, other organization and companies. 17 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#18Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Marie-France Tschudin President, Novartis Pharmaceuticals 18 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#19Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References +12% Growth drivers² Mature products³ 6.6 ■ 5.6 0.5 0.3 +35% 2.8 2.1 3.2 3.3 -4% Pharmaceuticals grew +12% in Q2 with growth drivers and launches showing strong momentum Pharmaceuticals net sales USD bn, % cc Launches1 Growth drivers showing strong momentum in Q2 vs. prior year ■ CosentyxⓇ and EntrestoⓇ together reached USD >2bn ZolgensmaⓇ up +48% YoY driven by geographic expansion llarisⓇ up +21% driven by Adult Onset Still Disease, Periodic Fever Syndrome New portfolio building foundation for future growth Q2 2020 Q2 2021 ■ +6% ■ Growth drivers and launches represent 51% of sales (up from 43% Q2 2020) CosentyxⓇ LCM progressing with regulatory milestones for pediatric portfolio LeqvioⓇ re-submitted in US – launch preparations on track 13.0 11.7 1.0 0.6 4.3 5.4 +29% 6.9 6.5' -10% H1 2020 H1 2021 LCM Lifecycle Management. All % growth relate to cc unless otherwise stated. 1. ZolgensmaⓇ, KesimptaⓇ, MayzentⓇ, BeovuⓇ, LuxturnaⓇ, LeqvioⓇ, EnerzairⓇ and AtecturaⓇ. 2. Cosentyx®, Entresto®, Xolair®, llaris®, XiidraⓇ and AimovigⓇ 3. All other brands. 19 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#20Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References CosentyxⓇ grew 21% in Q2, momentum expected to continue through 2021 Sales evolution USD m, % cc Ex-US US 944 330 614 +21% Double-digit growth expected to continue in H2 ■ US: growing volume in line with market across indications (vs. Q1) 1,175 460 ■ EU: leading biologic in PsO, leading originator biologic in SpA¹ ■ Growth continues in other markets including China post-NRDL LCM continues to reinforce differentiated efficacy and safety US Ped PSO approved EU/US submitted for jPsA & ERA ■ Ph3 readout for Hidradenitis Suppurativa on track for H2 2021 715 ■ US 300mg autoinjector approval expected H2 2021 ■ PSO dose flexibility approval expected H2 2021 EU / H1 2022 US Q2 2020 Q2 2021 NRDL National Reimbursement Drug List Ped PSO Pediatric Psoriasis PsO - Psoriasis SpA - Spondyloarthritis jPSA - Juvenile psoriasis arthritis ERA - Enthesitis related rheumatoid arthritis 1. TRX - EU data March 2021. 20 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#21US Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References EntrestoⓇ grew 46% in Q2; confident in future growth based on 1L guideline position, label update and geographic expansion Sales evolution USD m, % cc Ex-US Weekly NBRx1 New-to-brand prescriptions 7.0k Strong momentum worldwide ■ US: sales grew +31% to USD 405m ■ Ex-US: sales up +63% to USD 481m +46% 6.5k 6.0k 886 5.5k 5.0k 580 481 4.5k 272 4.0k 3.5k 405 308 3.0k 2.5k Q2 2020 Q2 2021 See slide 55 for references. NBRX New-to-brand Prescriptions Inhibitor HFrEF - Heart Failure with reduced Ejection Fraction 21 Investor Relations | Q2 2021 Results 03/19 - 05/19 - 07/19 - 09/19 - 11/19- 01/20 - 11/20 - 01/21 - 03/21 - 05/21 - 07/21 - ■ China now 2nd biggest market, accounting for - one fourth of ex-US sales Confidence in future growth trajectory ■ ACC ECDP2 and draft ESC guidelines³ recommend ARNI first-line for all appropriate HFrEF patients, including de novo initiation ■ Label expansion strengthens essential role of EntrestoⓇ across HF continuum ■ China approval in essential hypertension ACC - American College of Cardiology ECDP - Expert Consensus Decision Pathway ESC European Society of Cardiology ARNI - Angiotensin Receptor Neprilysin HF Heart Failure All % growth relate to cc unless otherwise stated. ✓ NOVARTIS | Reimagining Medicine#22Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References ZolgensmaⓇ grew 48% in Q2, potentially transformative efficacy in pre-symptomatic SMA Sales evolution USD m Ex-US US +48% 315 205 209 100 Q2 highlights ■ Continued strong sales growth with expanding access in Europe and emerging markets ■ Stable US business, driven by incident patients Approval in 41 countries; access pathways in 19 countries ■ 1.4k+ patients have been treated with ZolgensmaⓇ worldwide¹ Future growth drivers ☐ ☐ 105 106 Q2 2020 Q2 2021 Reimbursement: Implementation of H1 milestones (e.g. NHS)² and global expansion ■ Newborn screening: met target in US of >80%, on track for 20% in EU by end 2021 New data reinforce strong clinical benefit³ Age-appropriate development when used presymptomatically (SPR1NT) and consistent, significant benefit in symptomatic children (STR1VE-EU) ■ Reinforces ZolgensmaⓇ as foundational therapy for both presymptomatic and symptomatic children with SMA 1. Commercially, via managed access programs and in clinical trials. 2. NHS: National Health Service in England. 3. Presented at European Academy of Neurology (EAN) 2021. 22 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#23Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References KesimptaⓇ launch momentum continues - demand expected to double in H2 vs. H1 Launch progress in US NBRX +71%, 2nd highest NBRx share ahead of AubagioⓇ and TecfideraⓇ USD 66m Q2 sales, +58% QoQ1 KesimptaⓇ NBRX² New-to-brand prescriptions +71% >5k patients treated, 2x vs. Q1 51% of patients naive or first switch 1,832 <5 days to 1st dose in 80% of patients 1,074 >500 new prescribers vs. Q1 Q1 2021 Q2 2021 Foundation for continued growth Dynamic market recovery as vaccination campaign progresses Expansion of B-cell market as shift to high-efficacy therapies continues Differentiation based on unique PIRA and IgG data Growing awareness and familiarity with KesimptaⓇ to drive broader adoption Launch in 13 markets expected by year end 2021 PIRA - Progression independent of relapses IgG - Immunoglobulin G 1. Excluding 9m adjustment related to faster than expected conversion from free to paid product in prior quarter. 2. Cumulative NBRx for the quarter. 23 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#24Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References - Leqvio® – resubmission of NDA filed with FDA; preparing to launch innovative models to address access, adherence, affordability filed; PDUFA action date Jan 1, 2022 80% of patients not at goal Addressing access, adherence, affordability US ASCVD population¹ PCSK9i abandonment by OOP cost4 Progress since Q1 US: NDA resubmission 66% 41% 30m 22% 9% 0 40-50 75-125 250-500 Co-pay (USD) Diagnosed Statin treated 20m -80% At LDL-C goal² 4m Anticipated payer mix & co-pay for LeqvioⓇ at launch5 Medicare Part B (39%) 80% pay as little as 0 USD Non-statin therapy³ 1m Medicare Advantage (19%) 0-20% co-insurance Eligible patients pay as little as 0 USD <10 USD Commercial (34%) Other (8%) UK: on track for launch Q3 2021 V-INITIATE started to explore "LeqvioⓇ first" strategy directly after statins7 V-INCEPTION commenced to investigate Leqvio® initiation after recent ACS events? See slide 55 for references. ASCVD - Atherosclerotic Cardiovascular Disease LDL-C - Low Density Lipoprotein Cholesterol ACS Acute Coronary Syndrome 24 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#25Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Susanne Schaffert President, Novartis Oncology 25 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#26Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Oncology grew 7% in Q2 despite continued COVID-19 impact +7% 3.9 3.5 0.1 Oncology net sales USD bn, % cc Launches1 Growth drivers² Base business, Gx3 Solid Q2 performance fueled by growth drivers and recent launches ■ Growth drivers and recent launches now constitute 50% of sales (up from 45% Q2 2020) Key drivers: 0.1 1.5 1.8 +19% - Kisqali® Q2 sales USD 225m, +36% JakaviⓇ Q2 sales USD 398m, +19% 2.0 2.0' -3% - KymriahⓇ Q2 sales USD 147m, +19% Q2 2020 Q2 2021 - +4% 7.7 7.2 0.2 0.3 PromactaⓇ/Revolade® Q2 sales USD 513m, +18% ■ COVID-19 continues to impact diagnosis and treatment rates in certain segments (e.g. hospital-initiated therapies and breast cancer) Ongoing Gx impact including Glivec®, Exjade®/JadenuⓇ, AfinitorⓇ 2.9 3.5 +17% 4.1 3.91 -6% H1 2021 H1 2020 1. Launches include Piqray®, Adakveo® and TabrectaⓇ 2. Growth drivers include PromactaⓇ/Revolade®, Tafinlar+ MekinistⓇ, Kisqali®, LutatheraⓇ, KymriahⓇ and JakaviⓇ (marketed by Novartis ex-US). 3. Base business - other brands. Gx include AfinitorⓇ, Exjade® / JadenuⓇ, GlivecⓇ and SandostatinⓇ All % growth relate to cc unless otherwise stated. 26 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#27Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Key growth drivers accelerating in the US, while market still recovering from COVID-19 COVID-19 continues to weigh on US Oncology market Biopsy rates remain suppressed (%) - Breast Melanoma Lung Q2 showing partial recovery in US with growth drivers and recent launches accelerating USD m, % cc Launches1 Growth drivers² 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr +10% vs. PY Pre- COVID 133 120 ■ Growth drivers and launches contribute 49% of sales (up from 47% Q1 2021) ☐ ◉ PromactaⓇ USD 235m in Q2, +7% QoQ KisqaliⓇ USD 83m in Q2, +17% QoQ TafinlarⓇ+MekinistⓇ USD 151m in Q2, +8% QoQ Piqray®, TabrectaⓇ and AdakveoⓇ together USD 133m in Q2, +11% QoQ 584 616 ☐ Q1 2021 Q2 2021 1. Launches include Piqray®, AdakveoⓇ and TabrectaⓇ 2. Growth drivers include PromactaⓇ/Revolade®, TafinlarⓇ+ MekinistⓇ, KisqaliⓇ, LutatheraⓇ, KymriahⓇ 27 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#28Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References KisqaliⓇ grew 36% in Q2 with share gains ex-US Sales evolution USD m, % cc Ex-US US Strength of OS data in aBC is driving differentiation in the class Updated OS data from MONALEESA-3 presented at ASCO showed prolonged and consistent OS benefit with a median OS of ~4.5 years1 Only CDK 4/6i to demonstrate OS benefit in 2 Ph3 trials and longest median OS +36% 225 KisqaliⓇ gaining growth momentum despite slow market recovery 159 142 80 79 Q2 2020 Ex-US: Continued strong double-digit growth, with uptake driven by patient share gains in Europe; market leader in pre-menopausal setting in France, Italy and Spain ■ US: Q2 sales +17% vs. Q1, benefitting from higher demand due to increased field force reach coupled with targeted digital engagement Potential to become the only CDK4/6i in intermediate and high-risk eBC NATALEE adjuvant study completed enrollment; readout expected in 2022 83 ■ Q2 2021 aBC advanced breast cancer eBC early breast cancer 1. Intent to treat population. 28 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#29Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 177Lu-PSMA-617 launch preparations are progressing, ready to meet immediate launch demand upon approval in US Prognosis remains poor for patients with mCRPC Most diagnosed cancer in men¹ 2nd >80% Of patients metastatic at the time of CRPC diagnosis² ~10 Months median OS on available treatment options³ Building foundation for strong launch upon approval in US ■ 177 Lu-PSMA-617 uniquely positioned to address unmet needs in mCRPC with strong data on OS (median OS 15.3 months) and rPFS Disease state education campaign on PSMA as an important phenotypic biomarker ■ Growth in PSMA awareness from 31% to 66% over last 12 months4 Focused on activating >200 top treatment centers at launch for PSMA ■ Expecting gradual ramp-up due to diagnostic, process set-up, licensure FDA BTD granted in June 2021 ■ Filing to FDA on track for H2 2021 See slide 55 for references. 29 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#30Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Preparing to launch asciminib, the first STAMP inhibitor with potential to transform the standard of care in CML Asciminib Ph3 study in 3L+ CML: Nearly doubled MMR rate at Week 24 % of patients 25.5% ~2x1 13.2% Asciminib N=157 Bosutinib N=76 Unmet need in later lines of CML remains high ■ ~15% of CML patients progress to 3L ☐ Up to 55% of patients are intolerant to a previous TKI Ready to launch the first STAMP² inhibitor in H1 2022 ■ 75% aided awareness on asciminib / MoA ahead of launch ■ Submissions to FDA and EMA in 3L CML achieved in June 2021 ■ 2 FDA BTDs, RTOR and Fast Track designation received Blockbuster potential in 3L CML (incl. T3151) Potential to provide the best benefit-risk profile in 1L CML ☐ ■ ~50% of patients relapse on imatinib or are refractory/intolerant to imatinib³ >30% of patients suffer from TKI-related non-hematological AES4 In earlier lines of CML treatment, asciminib may prevent resistance to currently available TKIs by combatting emergence of mutations at BCR-ABL1 ATP binding site Initiating Ph3 study of asciminib vs. investigator-selected TKI; FPFV in Q4 2021 See slide 55 for references. 30 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#31Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References For Oncology, 2021 is a breakthrough year of delivering transformative innovation Readouts 177Lu-PSMA-617 Ph3 - mCRPC Submissions JAKAVI ruxolitinib Iptacopan Ph2 - PNH Canakinumab Ph3 NSCLC 2L TABRECTA (capmatinib) tablets Asciminib Alpelisib Ph3 - PROS KYMRIAH™ (tisagenlecleucel) Ph2 - FL KYMRIAH™ (tisagenlecleucel) Ph3 GEP NET (OS) LUTATHERA Designations EU, JP in a/c GVHD Asciminib FDA BTD in 3L CML EU in NSCLC Sabatolimab FDA Fast Track in MDS US, EU in CML 3L Alpelisib 177Lu-PSMA-617 EU Orphan designation in PROS FDA BTD in mCRPC 177Lu-PSMA-617 US, EU in mCRPC KYMRIAH™ (tisagenlecleucel); Spenden for infusan Canakinumab US, EU and JP in FL US in aNHL 2L Canakinumab Ph3 NSCLC 1L US in NSCLC 1L1 KYMRIAH™ (tisagenlecleucel) fr Ph2aNHL 2L S Tislelizumab US in 2L ESCC KISQALI ribociclib Ph3 - HR+ HER2- ABC (M-2 OS) Tislelizumab US in NSCLC Alpelisib US in PROS 1. Depending on timing of final read-out submission may move to early 2022 31 Investor Relations | Q2 2021 Results ✓ Achieved Readout not supportive 1 NOVARTIS | Reimagining Medicine#32Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Harry Kirsch Chief Financial Officer Financial review and 2021 guidance 32 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#33Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Solid H1 performance despite continued impact of COVID-19 Group¹ USD million Q2 Change vs. PY H1 Change vs. PY 2021 2021 % USD % cc % USD % cc Net Sales 12,956 14 9 25,367 7 3 Core Operating income 4,345 18 13 8,302 6 2 Operating income 3,479 48 41 5,894 16 12 Net Income 2,895 55 49 4,954 23 19 Core EPS (USD) 1.66 22 16 3.17 9 5 EPS (USD) 1.29 57 52 2.20 24 24 21 Free Cash Flow 4,235 17 5,832 3 Q2 ex. PY forward purchasing de-stocking²: Sales +5%; Core Oplnc +4% 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Financial Report. 2. Growth excluding prior year COVID-19 related forward purchasing reversal is a non-IFRS measure, an explanation for this measure can be found on page 61 of the Condensed Interim Financial Report. All % growth relate to cc unless otherwise stated. 33 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#34Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Strong Q2 Innovative Medicines division performance Innovative Medicines Sandoz Group Q2 2021 Net sales Core Oplnc Core Core margin change vs. PY % CC1 change vs. PY % CC1 margin %1 change vs. PY %pts cc1 10 Q2 2021 ex. PY forward purchasing de-stocking² Net sales change vs. PY %, cc1 Core Oplnc Core margin change vs. PY %, CC1 change vs. PY %pts cc1 14 37.3 1.3 7 6 -0.2 3 21.7 -0.4 -1 -1.8 3 33.5 1.2 5 4 -0.3 9 13 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Financial Report. 2. Growth ex. PY forward purchasing de-stocking is a non-IFRS measure; explanation can be found on page 61 of Condensed Interim Financial Report. 34 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#35Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 2021 Novartis full year guidance Barring unforeseen events; growth vs. PY in cc Group | full year guidance¹ vs. PY (cc) Group sales expected to grow low to mid single digit ■ IM Division expected to grow mid single digit ☐ ■ Sandoz expected to decline low to mid single digit Group core operating income expected to grow mid single digit, ahead of sales IM Division expected to grow mid to high single digit, ahead of sales Sandoz expected to decline low to mid teens 1. Key assumptions: Our guidance assumes that we see a continuation of the return to normal global healthcare systems including prescription dynamics, particularly oncology, in H2 2021 In addition, we assume that no GilenyaⓇ and no Sandostatin® LAR generics enter in 2021 in the US 35 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#36Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References H2 2021 sales and core Oplnc growth expected to accelerate as healthcare systems return to normal Group growth vs. PY illustrative %pts, cc Sales 3% Mid single digit Low to mid single digit ☐ H2 2021 sales¹ Growth acceleration as we expect continuation of the return to normal global healthcare systems including prescription dynamics, particularly in oncology H1 2021 H2 2021 FY 2021 ■ Sandoz stabilization Core Oplnc 2% H1 2021 High single digit Mid single digit H2 2021 FY 2021 1. Assumes no GilenyaⓇ and no Sandostatin® LAR generics enter in the US. 36 Investor Relations | Q2 2021 Results H2 2021 Core operating income ■ Driven by higher sales Increased investments in growth drivers as markets reopen, and pipeline (incl. tislelizumab) Ongoing productivity programs NOVARTIS | Reimagining Medicine#37Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Expected currency impact for H2 and full year 2021 Currency impact vs. PY %pts, assuming mid-July exchange rates prevail in 2021 I 3 FX impact on Net sales 5 0 I I I FY Q1 Q2 I 2020 I Actual Simulation 37 Investor Relations | Q2 2021 Results 1 2 0 FX impact on Core operating income -4 Q3 Q4 FY FY I 2021 2020 I 5 3 2 to 3 1 to 2 0 to 1 Q1 Q2 Q3 Q4 FY 2021 1 NOVARTIS | Reimagining Medicine#38Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Vas Narasimhan Chief Executive Officer 38 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#39Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 2021 catalysts maintaining long-term momentum Potential catalysts Selected examples Major approvals KesimptaⓇ (EU/JP) RMS EntrestoⓇ (US) HFPEF Achieved Readout not supportive Major Alpelisib (BYL719) PROS Asciminib (ABL001) CML KymriahⓇ FL submissions¹ 177 Lu-PSMA-617 Major readouts Enabling submission 2021 Enabling submission 2022 Others mCRPC KymriahⓇ aNHL 2L Ligelizumab (QGE031)5 CSU Iptacopan (LNP023) Ph2 IgAN Pivotal study starts Iptacopan (LNP023) Ph3 IgAN Ligelizumab (QGE031) CINDU Canakinumab (ACZ885)³ NSCLC 1L CosentyxⓇ HS Iptacopan (LNP023) ✓ Ph2 PNH Iptacopan (LNP023) ✓ Ph3 C3G 177Lu-PSMA-617 pre-taxane 1. First submission in any market. 2. Resubmitted to FDA. 3. Depending on timing of final readout submission may move to early 2022. composite endpoint. The safety profile of EntrestoⓇ was confirmed. No submission planned. 5. Q4/2021-Q1/2022 potential COVID impact. submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial. Cosentyx® (US✓/JP/CN) Pediatric psoriasis JakaviⓇ Acute and chronic GVHD Leqvio® (US)² Hyperlipidemia EntrestoⓇ4 Post-AMI No submission planned Sabatolimab (MBG453)6 MDS Iptacopan (LNP023) Ph2 C3G Iptacopan (LNP023) Ph3 aHUS 177Lu-PSMA-617 MHSPC BeovuⓇ DME Tislelizumab (VDT482) 2L esophageal cancer, NSCLC KisqaliⓇ Breast cancer (MONALEESA-2) Ligelizumab (QGE031) Food allergy 4. Numerical trends consistently favored EntrestoⓇ vs. active comparator but did not meet primary 6. Planned DMC readout for CR completed, study continues blinded to PFS readout, with 39 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#40Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Consistent long-term performance driving confidence for the future Strong performance in Q2 driven by the momentum of key growth drivers including Cosentyx®, EntrestoⓇ, ZolgensmaⓇ and Oncology portfolio Pipeline of novel medicines continues to progress including positive readouts in diseases with high unmet need with iptacopan, ZolgensmaⓇ and 177 Lu-PSMA-617 Reconfirming FY 2021 guidance and our commitment to drive long-term accretive growth 40 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#41Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Appendix 41 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#42Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Key growth drivers and launches continue momentum in H1 H1 key growth driver sales momentum¹ Driving portfolio rejuvenation Sales Growth vs. PY Growth vs. PY USD Million USD Million CC Entresto 1,675 526 40% Key growth drivers and launches 49% of IM sales, growing 24% in H1 sacubitnivalsartan Cosentyx (secukinumab AimovigⓇ 2,228 354 16% 49% KesimptaⓇ MayzentⓇ zolgensma 634 259 63% PiqrayⓇ 42% PROMACTA® 976 151 16% XiidraⓇ (eltrombopag) LutatheraⓇ JAKAVI 761 133 14% ruxolitinib 32% Kesimpta 116 116 nm (ofatumumab) 24% KISQALI 420 100 28% ribociclib Xolair 690 94 9% Omalizumab ILARIS 503 90 20% (canakinumab) KymriahⓇ KisqaliⓇ llarisⓇ ZolgensmaⓇ Jakavi® Tafinlar+MekinistⓇ PromactaⓇ EntrestoⓇ KYMRIAH 298 87 35% (tisagenlecleucel) 818 81 7% CosentyxⓇ Other¹ Tafinlar +Mekinist MAYZENT. 124 (siponimod) tablets 24 H1 2018 H1 2019 H1 2020 H1 2021 60 89% nm not meaningful 1. Includes Xolair®, Beovu®, AdakveoⓇ, Luxturna Ⓡ, Tabrecta®, Enerzair ®, AtecturaⓇ and LeqvioⓇ 1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 42 Investor Relations | Q2 2021 Results U NOVARTIS | Reimagining Medicine#43Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Solid H1 Innovative Medicines division performance Innovative Medicines Sandoz Group H1 2021 Net sales Core Oplnc Core Core margin change vs. PY % CC1 change vs. PY % CC1 margin change vs. PY %pts cc1 % 5 6 36.8 0.4 -5 -19 20.5 -3.7 3 2 32.7 -0.4 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Financial Report. 43 Investor Relations | Q2 2021 Results U NOVARTIS | Reimagining Medicine#44Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials H1 2021 free cash flow growing to USD 5.8bn Group free cash flow¹ USD bn, % USD 5.7 +3% + 5.8 H1 2020 H1 2021 Key drivers vs. PY: - Higher divestment proceeds Tislelizumab in-licensing (upfront payment USD 650m) 1. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. 44 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#45Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Net debt increased to USD 28.5bn mainly due to dividend and buybacks, partly offset by strong FCF USD bn -24.5 -4.0 -2.6 0.4 -28.5 -7.4 -0.2 5.8 Dec. 31, 2020 Dividends M&A transactions Free Cash Flow Treasury share transactions, net Others June 30, 2021 45 Investor Relations | Q2 2021 Results U NOVARTIS | Reimagining Medicine#46Financial review Conclusion Appendix Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview References Innovation: Clinical trials Regulatory 2021 key pipeline milestones¹ H1 2021 EntrestoⓇ HFPEF (US) H2 2021 CosentyxⓇ Pediatric psoriasis (US ✓ CN/JP) ✓ Achieved Readout not supportive decisions and opinions KesimptaⓇ Relapsing MS (EU/JP) Major Leqvio® Hyperlipidemia (US)² Asciminib (ABL001) CML 3L (JP) expected JakaviⓇ submissions TabrectaⓇ BeovuⓇ Acute and chronic GVHD (EU/JP) ✓ NSCLC (EU) DME (US/EU) BeovuⓇ H2-2021 Asciminib (ABL001) CML 3L (US/EU) CosentyxⓇ JIA (US/EU) Major Iptacopan (LNP023) Ph2 - IgAN expected trial readouts* Iptacopan (LNP023) Ph2 - C3G EntrestoⓇ Ph3 Post-AMI Canakinumab - Ph3 NSCLC 2L (ACZ885) 177Lu-PSMA-617 CosentyxⓇ Ph3 - mCRPC Ph3 - JIA H2 20213 ECF843 4 6 Ligelizumab (QGE031) KisqaliⓇ Remibrutinib (LOU064) CosentyxⓇ Ph3 - HS Alpelisib (BYL719) KymriahⓇ 177 Lu-PSMA-617 Tislelizumab (VDT482) Tislelizumab (VDT482) Canakinumab (ACZ885) DME (JP) PROS (US) r/r Follicular lymphoma (US/EU/JP) mCRPC (US/EU) 2L esophageal cancer (US) NSCLC (US) Ph3 - NSCLC 1L Ph2 - Dry eye Ph3 - CSU5 Ph3 aBC (MONALEESA-2 OS) - Ph2 - CSU 8 Sabatolimab (MBG453) Ph2 - MDS7 KymriahⓇ - Ph3 aNHL 2L 2. Resubmitted to FDA 3. Ph2 interim data presented 4. Numerical trends *Achieved on-time readout of data, irrespective of trial outcome. 1. 2021 Key milestone table may evolve based on read-out outcomes as well as BD&L activities. consistently favored EntrestoⓇ vs. active comparator but did not meet primary composite endpoint. The safety profile of EntrestoⓇ was confirmed. No submission planned. 7. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial. 5. Q4/2021-Q1/2022 potential COVID impact. 6. Negative readout 8. Program discontinued in broad population of moderate to severe DED. 46 Investor Relations | Q2 2021 Results U NOVARTIS | Reimagining Medicine#47Financial review Conclusion Appendix Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Our pipeline projects at a glance References Innovation: Clinical trials Phase 1/2 Phase 3 Registration Total ONCOLOGY 44 26 3 73 PHARMACEUTICALS Cardiovascular, Renal, Metabolism Immunology, Hepatology, Dermatology Neuroscience 58 23 3 84 6 7 1 14 Ophthalmology 265 27 8 2 2 37 0 8 3 0 8 Respiratory Global Health 7 2 0 9 7 1 0 8 BIOSIMILARS 0 2 0 2 Total 102 51 6 159 47 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#48Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 1 (1 of 2) ADPT01 ADPT03 Oncology Code AAA603 AAA602 Name 177 Lu-NeoB 177Lu-PSMA-R2 ADPT01 ADPT03 CSJ137 CSJ137 DKY709 DKY709spartalizumab HDM201 HDM201 + MBG453, venetoclax JBH492 JBH492 JDQ443 JDQ443 KRAS Inhibitor JEZ567 JEZ567 CD123 CAR-T KAZ954 KAZ954 LXF821 LXF821 LXH254 LXH254 MAK683 MCM998 MIK665 MAK683 MCM998, LXG250 MIK665 NIS793 NIS793, spartalizumab Mechanism Radioligand therapy target GRPR Radioligand therapy target PSMA BCL11A Growth factor inhibitor Novel immunomodulatory agent MDM2 inhibitor EGFR CAR-T CRAF inhibitor EED inhibitor BCMA CAR-T, CD19 CAR-T MCL1 inhibitor TGFB1 inhibitor Indication(s) Multiple solid tumors Prostate cancer Colorectal cancer (combos) Sickle cell anemia Anaemia Cancers Haematological malignancy Haematological malignancy Solid tumors Acute myeloid leukaemia Solid tumors Glioblastoma multiforme Solid tumors (combo) Cancers Multiple myeloma Acute myeloid leukaemia (combo) Solid tumors NIZ985 NIZ985, spartalizumab NZV930 PDR001 PHE885 PHE885 SQZ622 SQZ622 TNO155 TNO155 VAY736 ianalumab + ibrutinib VOB560 VOB560 VPM087 WNT974 gevokizumab WNT974+ spartalizumab WVT078 WVT078 YTB323 YTB323 ± ibrutinib NZV930, spartalizumab, NIR178 spartalizumab IL-15 agonist CD73 antagonist PD1 inhibitor BCMA cell therapy CD123xCD3 modulator SHP2 inhibitor BAFF-R inhibitor IL-1 beta antagonist Porcupine inhibitor CD19 CAR-T Solid tumors Solid tumors Solid tumors (combo) Multiple Myeloma Acute myeloid leukaemia Solid tumors (single agent) Haematological malignancy Cancers Colorectal cancer, 1st line Solid tumors Multiple myeloma Haematological malignancy - 48 Investor Relations | Q2 2021 Results References Innovation: Clinical trials 38 lead indications Lead indication Solid tumors (combo) Solid tumors (combo) NOVARTIS | Reimagining Medicine#49Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 1 (2 of 2) Immunology, Hepatology, Dermatology Mechanism Code Name CEE321 CEE321 DFV890 DFV890 FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 NG1226 NG1226 Neuroscience Name Code OAV201 OAV201 (AVXS-201) NIO752 NIO752 LMI070 branaplam Pan JAK inhibitor Indication(s) Atopic dermatitis Anti-inflammatory therapy Non-alcoholic steatohepatitis (NASH) Autoimmune indications Sjögren's Tendinopathy Systemic lupus erythematosus Mechanism Indication(s) MECP2 gene therapy Rett syndrome Tau antagonist Neurodegenerative diseases mRNA splicing modulator Huntington's disease Ophthalmology Code MHU650 Name Mechanism MHU650 49 Investor Relations | Q2 2021 Results Respiratory Disease Code Name LTP001 LTP001 NCJ424 NCJ424 Mechanism References Innovation: Clinical trials 38 lead indications Lead indication Indication(s) Respiratory diseases Respiratory diseases Cardiovascular, Renal, Metabolism Code Name MBL949 MBL949 Mechanism Indication(s) Obesity related diseases Global Health Indication(s) Code KAF156 Diabetic eye diseases INE963 Name ganaplacide INE963 Mechanism Indication(s) Malaria prophylaxis Malaria, uncomplicated NOVARTIS | Reimagining Medicine#50Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 2 Oncology Ophthalmology References Innovation: Clinical trials 27 lead indications TRPV1 antagonist Reduction of disulfide bonds Indication(s) Retinitis pigmentosa Diabetic retinopathy Chronic ocular surface pain Presbyopia Code CPK850 CPK850 LKA651 LKA651 SAF312 SAF312 UNR844 UNR844 Name Mechanism RLBP1 AAV EPO inhibitor Acute GVHD, pediatrics Chronic GVHD, pediatrics Code Name BYL719 alpelisib BLZ945 BLZ945 DRB436 Tafinlar® + MekinistⓇ TabrectaⓇ INC280 INC424 Jakavi® LXH254 LXH254 MBG453 sabatolimab NIR178 NIR178, spartalizumab NIS793 NIS793 Mechanism PI3Ka inhibitor CSF-1R inhibitor BRAF inhibitor + MEK inhibitor Met inhibitor JAK1/2 inhibitor CRAF inhibitor TIM3 antagonist Ad2AR inhibitor, PD1 inhibitor TGFB1 inhibitor PD1 inhibitor P-selectin inhibitor Indication(s) PIK3CA-related overgrowth spectrum Solid tumors HGG/LGG, pediatrics Non-small cell lung cancer (Combo) Myelofibrosis (combination) Melanoma (combo) Unfit acute myeloid leukaemia Cancers Pancreatic cancer Metastatic melanoma (combo) Sickle cell anaemia with crisis, pediatrics PDR001 Spartalizumab SEG101 Adakveo® Immunology, Hepatology, Dermatology Code Name ADPT02 ADPT02 AIN457 Cosentyx® Mechanism CFZ533 iscalimab CMK389 CMK389 LJN452 tropifexor +licogliflozin LNA043 LNA043 LOU064 remibrutinib LRX712 LRX712 LYS006 LYS006 Indication(s) Non-alcoholic steatohepatitis (Combos) IL17A inhibitor Giant cell arteritis CD40 inhibitor IL-18 inhibitor FXR agonist ANGPTL3 agonist BTK inhibitor Renal Tx Atopic dermatitis Non-alcoholic steatohepatitis (Combos) Knee osteoarthritis Chronic spontaneous urticaria Sjögren's Osteoarthritis Sjögren's Lichen planus Hidradenitis Liver Tx Respiratory Disease Code CMK389 CSJ117 QBW251 QMF149 Name Mechanism CMK389 IL-18 inhibitor CSJ117 icenticaftor Atectura® TSLP inhibitor CFTR potentiator Combo Cardiovascular, Renal, Metabolism Code Name CFZ533 iscalimab Mechanism CD40 inhibitor HSY244 HSY244 Acne Colitis ulcerative Hidradenitis LNP023 iptacopan CFB inhibitor NLRC4-GOF indications Sjögren's Autoimmune hepatitis MAS825 MAS825 VAY736 ianalumab Anti-inflammatory BAFF-R inhibitor Systemic lupus erythematosus Neuroscience Code Name BLZ945 BLZ945 MIJ821 MIJ821 OAV101 AVXS-101 Mechanism CSF-1R inhibitor NR2B inhibitor Survival motor neuron (SMN) gene therapy Indication(s) Amyotrophic lateral sclerosis Depression SMA IT¹) 1. Preclinical studies to address partial clinical hold completed. 50 Investor Relations | Q2 2021 Results Global Health Code AFQ056 KAE609 KAF156 Name mavoglurant cipargamin ganaplacide LXE408 LXE408 Indication(s) Pulmonary sarcoidosis Asthma Chronic obstructive pulmonary disease Asthma, pediatrics Lead indication Bronchiectasis Indication(s) Lupus nephritis Type 1 diabetes mellitus Atrial fibrillation Membranous nephropathy Atypical haemolytic uraemic syndrome Mechanism mGluR5 antagonist PfATP4 inhibitor Indication(s) Cocaine use disorder Malaria, severe Malaria, uncomplicated Malaria, uncomplicated Protozoan inhibitor Visceral leishmaniasis U NOVARTIS | Reimagining Medicine#51Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 3 References Innovation: Clinical trials 6 lead indications Lead indication Oncology Code Name AAA617 177 Lu-PSMA-617 Mechanism Indication(s) Metastatic castration-resistant prostate cancer (mCRPC) Radioligand therapy target PSMA mCRPC, pre-taxane Metastatic hormone sensitive prostate cancer (mHSPC) Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 AAA6011) LutatheraⓇ ABL001 asciminib BCR-ABL inhibitor ACZ885 canakinumab IL-1b inhibitor BYL719 CTL019 Piqray® KymriahⓇ PI3Ka inhibitor CD19 CAR-T tumors (GEP-NET 1L G3) Neuroscience Code AMG334 AimovigⓇ Name BAF312 Mayzent® Respiratory Disease Code Name IGE025 XolairⓇ Mechanism CGRPR antagonist S1P1,5 receptor modulator Indication(s) Migraine, pediatrics Multiple sclerosis, pediatrics Mechanism IgE inhibitor Indication(s) Food allergy Auto-injector Cardiovascular, Renal, Metabolism Chronic myeloid leukemia, 1st line Non-small cell lung cancer (NSCLC), 1L HER2+ adv BC NSCLC, adjuvant Triple negative breast cancer Ovarian cancer Code Name KJX839 Leqvio® LCZ696 EntrestoⓇ LNP023 Iptacopan BRAF inhibitor + MEK inhibitor Thrombopoietin receptor (TPO-R) agonist DRB436 ETB115 Tafinlar + Mekinist PromactaⓇ LEE011 Kisqali® CDK4/6 Inhibitor MBG453 Sabatolimab TIM3 antagonist r/r Follicular lymphoma 1L high risk acute lymphocytic leukaemia, pediatrics & young adults Relapsed/refractory aggressive non-Hodgkin's lymphoma Thyroid cancer Radiation sickness syndrome HR+/HER2- BC (adj) Myelodysplastic syndrome 2L ESCC 1L Nasopharyngeal Carcinoma 1L ESCC 1L Hepatocellular Carcinoma TQJ230 Pelacarsen Non-small cell lung cancer 1L Gastric cancer Localized ESCC Biosimilars Code 1L Small Cell Lung Cancer Name GP2411 denosumab SOK583 aflibercept 1L Bladder Urothelial Cell Carcinoma VDT482 tislelizumab PD1 inhibitor Mechanism siRNA (regulation of LDL-C) Angiotensin receptor/neprilysin inhibitor CFB inhibitor ASO targeting Lp(a) Indication(s) CVRR-LDLC Hyperlipidemia, pediatrics Congestive heart failure, pediatrics²) Paroxysmal nocturnal haemoglobinuria IgA nephropathy C3 glomerulopathy Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) (CVRR-Lp(a)) Mechanism anti RANKL mAb VEGF inhibitor Indication(s) Denosumab BioS Ophthalmology indication (as originator) Immunology, Hepatology, Dermatology Code Name AIN457 Cosentyx® QGE031 ligelizumab Mechanism IL17A inhibitor IgE inhibitor Indication(s) Lupus Nephritis AS H2H Hidradenitis suppurativa Psoriatic arthritis (IV formulation) Ankylosing spondylitis (IV formulation) Chronic spontaneous urticaria Chronic inducible urticarial (CINDU) 1. 177 Lu-dotatate in US. 2. Approved in US. 3. Under evaluation. 51 Investor Relations | Q2 2021 Results Ophthalmology Code Name RTH258 BeovuⓇ Mechanism VEGF inhibitor Global Health Food allergy Code COA566 Name Coartem® Mechanism Indication(s) Diabetic retinopathy Retinal vein occlusion³ Diabetic macular edemal Indication(s) Malaria, uncomplicated (<5kg patients) U NOVARTIS | Reimagining Medicine#52Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in registration Oncology Code Name Mechanism Indication(s) References Innovation: Clinical trials Cardiovascular, Renal, Metabolism Chronic GVHD Code Name KJX839 Leqvio® Mechanism siRNA (regulation of LDL-C) Indication(s) Hyperlipidemia1 INC424 Jakavi® ABL001 asciminib JAK1/2 inhibitor BCR-ABL inhibitor Acute GVHD Chronic myeloid leukemia, 3rd line Immunology, Hepatology, Dermatology Code AIN457 Name Cosentyx® 1. Approved in EU. Mechanism IL17A inhibitor 52 Investor Relations | Q2 2021 Results Indication(s) Cosentyx 300mg auto-injector and pre-filled syringe Juvenile idiopathic arthritis 2 lead indication Lead indication NOVARTIS | Reimagining Medicine#53NEW INDICATIONS Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Financial review Conclusion Appendix Novartis submission schedule New Molecular Entities: Lead and supplementary indications LEAD INDICATIONS 2021 177Lu-PSMA-617 AAA617 mCRPC 3L asciminib ABL001 CML 3L tislelizumab VDT482 2L esophageal cancer 2022 Lead ligelizumab QGE031 2023 Lead iptacopan Lead CSU Lead sabatolimab¹ Lead MBG453 Lead HR-MDS tislelizumab LCM tislelizumab LCM VDT482 VDT482 NSCLC 1L Nasopharyngeal Carcinoma LNP023 PNH 2024 SAF312 COSP Lead UNR844 Presbyopia Lead References Innovation: Clinical trials 177 Lu-NeoB AAA603 Multiple Solid Tumors 177 Lu-PSMA-R2 AAA602 Prostate cancer branaplam LMI070 Huntington's disease CEE321 Atopic Dermatitis cipargamin KAE609 Malaria severe CPK850 ≥2025 Lead ganaplacide KAF156 Malaria uncomplicated Lead iscalimab CFZ533 Knee osteoarthritis Lead MIJ821 Depression Lead Lead NIS793 Lead Solid tumors Renal Tx Lead ianalumab Lead OAV201 Lead VAY736 AVXS-201 Sjögren's syndrome Rett syndrome Lead icenticaftor QBW251 COPD Lead pelacarsen Lead TQJ230 CVRR-Lp(a) Lead LNA043 Lead remibrutinib LOU064 CSU Lead LXE408 Lead spartalizumab Lead RP Visceral leishmaniasis PDR001 Metastatic melanoma (combo) CSJ117 Lead LXH254 Lead TNO155 Lead Asthma Solid tumors (combo) Solid tumors gevokizumab VPM087 Lead mavoglurant Lead tropifexor&licogliflozin Lead AFQ056 1st line CRC / 1st line RCC Cocaine use disorder LJN452 NASH (combos) LCM ligelizumab QGE031 Food allergy 177Lu-PSMA-617 AAA617 Pre-taxane iptacopan LNP023 C3G LCM tislelizumab LCM 177Lu-PSMA-617 LCM VDT482 1L ESCC LCM tislelizumab VDT482 AAA617 MHSPC asciminib ABL001 CML 1L LCM iptacopan LNP023 iMN LCM LCM sabatolimab LCM cipargamin LCM iscalimab MBG453 KAE609 Localized ESCC Unfit AML Malaria uncomplicated iptacopan LCM tislelizumab LCM tislelizumab LCM ianalumab LNP023 IgAN tislelizumab VDT482 VDT482 VDT482 VAY736 1L Hepatocellular Carcinoma 1L Small Cell Lung Cancer АІН CFZ533 Liver Tx LCM iscalimab CFZ533 Sjögren's syndrome LCM ligelizumab QGE031 LCM CINDU LCM remibrutinib LCM LOU064 Sjögren's syndrome LCM tislelizumab LCM iptacopan LCM VDT482 1L Gastric Cancer 1L Bladder Urothelial Cell Carcinoma LNP023 aHUS 1. Filing opportunity in 2022 / 2023, based on PFS and/or OS outcomes from a dual approach based on parallel Phase 2 and Phase 3 trials. 53 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#54Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands References Innovation: Clinical trials 2021 alpelisib LCM BYL719 PROS Beovu LCM brolucizumab, RTH258 DME canakinumab¹ LCM Cosentyx 2022 secukinumab, AIN457 PSA IVIV Cosentyx secukinumab, AIN457 AS H2H Cosentyx 2023 LCM canakinumab ACZ885 Adjuvant NSCLC 2024 LCM Adakveo SEG101 LCM Aimovig Sickle cell anaemia with crisis ped erenumab, AMG334 Pediatric Migraine ≥2025 LCM Cosentyx LCM Leqvio LCM secukinumab, AIN457 Lupus Nephritis KJX839 CVRR-LDLC LCM Cosentyx LCM Beovu LCM aflibercept BioS secukinumab, AIN457 AS IVIV brolucizumab, RTH258 RVO4 SOK583 Neovascular age-related macular degeneration Cosentyx secukinumab, AIN457 Lichen Planus LCM Mayzent LCM siponimod, BAF312 Pediatric MS LCM Denosumab BioS Coartem LCM Beovu LCM Jakavi LCM Piqray LCM ACZ885 NSCLC 1L secukinumab, AIN457 Hidradenitis suppurativa GP2411 artemether + lumefantrine, COA566 brolucizumab, RTH258 ruxolitinib, INC424 alpelisib, BYL719 anti RANKL mAb Malaria uncompl., formula for <5kg Diabetic retinopathy Myelofibrosis (combination) HER2+ adv BC Cosentyx LCM Entresto EU² LCM Kisqali LCM Cosentyx LCM Kymriah LCM OAV101 LCM secukinumab, AIN457 sacubitril/valsartan, LCZ696 Juvenile idiopathic arthritis Pediatric CHF ribociclib, LEE011 HR+/HER2- BC (adj) secukinumab, AIN457 tisagenlecleucel, CTL019 GCA 1L high risk ALL, pediatrics & young adults AVXS-101 SMA IT Jakavi LCM Tafinlar + Mekinist LCM Lutathera LCM Jakavi LCM ruxolitinib, INC424 Chronic GVHD dabrafenib + trametinib, DRB436 HGG/LGG Pediatrics 177Lu-oxodotreotide³ GEP-NET 1L G3 ruxolitinib, INC424 Pediatrics Acute GVHD Jakavi LCM Xolair LCM Piqray LCM Jakavi LCM ruxolitinib, INC424 omalizumab, IGE025 alpelisib, BYL719 ruxolitinib, INC424 Acute GVHD Auto-injector TNBC Pediatrics Chronic GVHD Kymriah LCM Piqray LCM Leqvio LCM tisagenlecleucel, CTL019 alpelisib, BYL719 KJX839 aNHL 2L Ovarian cancer Ped Hyperlipidemia Kymriah LCM Promacta LCM Tafinlar+ Mekinist LCM tisagenlecleucel, CTL019 eltrombopag, ETB115 r/r Follicular lymphoma Radiation sickness syndrome dabrafenib + trametinib, DRB436 Thyroid cancer Xolair LCM omalizumab, IGE025 Food allergy 1. Depending on timing of final read-out submission may move to early 2022. 2. Approved in US. 3. 177Lu-dotatate in US. 4. Under evaluation. 54 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#55Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References References Consistent long-term performance 1 2 Cosentyx®, EntrestoⓇ, ZolgensmaⓇ, KisqaliⓇ, Mayzent®, Tafinlar+MekinistⓇ, JakaviⓇ, BeovuⓇ, XiidraⓇ, AimovigⓇ, XolairⓇ. LutatheraⓇ, KymriahⓇ, Piqray®, AdakveoⓇ, KesimptaⓇ, Leqvio®, TabrectaⓇ, Asciminib. 3 Brands with 2024 consensus sales lower than 2019 actual sales (Glivec®, Tasigna®, Afinitor®, VotrientⓇ, Promacta®, Exjade®, SandostatinⓇ®, Galvus®, GilenyaⓇ, LucentisⓇ). EntrestoⓇ 1 2 3 IQVIA National Prescription Audit 2021 Update to the 2017 ACC Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022 Update to ESC heart Failure guidelines as presented at ESC-HF (28 Jun - 1 Jul 20201). Complete and final guideline to be released in August 2021 LeqvioⓇ 1 2 3 4 5 6 7 Data on file; American Heart Association. Center for Health Metrics and Evaluation. Accessed at: https://healthmetrics.heart.org/prevalence-and-number-of-us-adults-eligible-for-and-currently-using-statin-therapy-nhanes-2011-2014/; Wong ND. Journal of Clinical Lipidology. 2016;10(5):1109-1118; American Heart Association/American Stroke Association. Cardiovascular Disease: A Costly Burden <70mg/dL Non-statin lipid lowering therapies include ezetimibe and PCSK9i mAbs. LAAD; IQVIA US Market Access Strategy Consulting. Percentages in table refer to share of eligible US population Medicaid, federal. In patients with elevated LDL-C despite treatment with maximally tolerated statin therapy. V-INITIATE NCT04929249; V-INCEPTION NCT04873934 Asciminib Difference: 12.2% (95% confidence interval: 2.19, 22.30, two-sided p-value: 0.029) per the Cochran-Mantel-Haenszel test which is stratified by baseline major cytogenetic response status, cut-off date 25-May-2020 Specifically Targeting BCR-ABL Myristoyl Pocket. 1 2 3 4 ELN recommendations 2019 Garcia-Gutierrez V and Hernandez-Boluda JC, Front. Oncol. 2019; 9:603 177Lu-PSMA-617 1 2 3 Epidemiology of Prostate Cancer. Rawla P., World J Oncol. 2019;10(2):63-89 Characterizing the castration-resistant prostate cancer population: a systematic review. M. Kirby et all., Int J Clin Pract. 2011;65(11):1180-92 In men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide, Smith et al., Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1, J Clin Oncol 34:3005-3013 4 Sartor et al, NEJM, 2021, DOI: 10.1056/NEJMoa210732 5 Novartis primary market research ATU, May 2020 & June 2021 55 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#56Participants Company overview Pharmaceuticals Oncology Financial performance CRM IHD Neuroscience Oncology Ophthalmology Financial review Conclusion Appendix Innovation: Pipeline overview Respiratory References Innovation: Clinical trials Sandoz Biopharmaceuticals Global Health Abbreviations Clinical Trials Update Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2b or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com 56 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#57Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Cardiovascular, Renal and Metabolic 57 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#58Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations EntrestoⓇ (ARNI) - Angiotensin II Receptor Neprilysin Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT02468232 PARALLEL-HF (CLCZ696B1301) Heart failure, reduced ejection fraction Phase 3 225 Time to the first occurrence of the composite endpoint - either cardiovascular (CV) death or heart failure (HF) hospitalization Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid/placebo of enalapril Enalapril 2.5 mg, 5 mg, 10 mg bid / placebo of sacubitril/valsartan Japanese heart failure patients (NYHA Class II-IV) with reduced ejection fraction Primary: Q1-2019 (actual); Extension (open-label): Q1-2021 (actual) Q1-2022 NCT02678312 PANORAMA HF (CLCZ696B2319) Heart failure in pediatric patients Phase 3 360 Part 1: Pharmacodynamics and pharmacokinetics of sacubitril/valsartan LCZ696 analytes Part 2: Efficacy and safety compared with enalapril Part 1: Sacubitril/valsartan 0.8 mg/kg or 3.1 mg/kg or both; 0.4 mg/kg or 1.6 mg/kg or both (single doses). Part 2: enalapril/placebo 0.2 mg/kg bid (ped. formulation 1mg/ml) and adult formulation (2.5, 5, 10 mg bid); Sacubitril/valsartan (LCZ696)/placebo: Ped. formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid) Pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction 2022; (Analysis of 110 pts from Part 2 formed the basis for pediatric submission in Apr-2019 and approval by the US FDA in Oct-2019 for the treatment of symptomatic HF with systemic left ventricular systolic dysfunction in children aged 1 year and older) TBD 58 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#59Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations EntrestoⓇ (ARNI) Study Indication Phase Patients Primary Outcome Measures Arms Intervention - Angiotensin II Receptor Neprilysin Inhibitor NCT02884206 PERSPECTIVE (CLCZ696B2320) Heart failure Phase 3 592 Change from baseline in the CogState Global Cognitive Composite Score (GCCS) Sacubitril/valsartan 50, 100, and 200 mg bid with placebo of valsartan Valsartan 40, 80, and 160 mg bid tablets with placebo for sacubitril/valsartan Patients with chronic heart failure with preserved ejection fraction NCT02924727 PARADISE-MI (CLCZ696G2301) Post-acute myocardial infarction Phase 3 5670 Time to the first occurrence of a confirmed composite endpoint (cardiovascular (CV) death, heart failure (HF) hospitalization, or outpatient heart failure) Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid; placebo for ramipril ; placebo for valsartan Ramipril 1.25 mg, 2.5 mg, and 5 mg bid; placebo for sacubitril/valsartan; placebo for valsartan Post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF Q2-2021 (actual) PARADISE-MI study design / baseline characteristics: published in Q2-2021 (actual) Data presentation at ACC Q2-2021 and plans for further scientific events Target Patients Read-out Milesstone(s) 2022 Publication TBD 59 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#60Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations EntrestoⓇ (ARNI) - Angiotensin II Receptor Neprilysin Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03066804 PARALLAX (CLCZ696D2302) Heart failure, preserved ejection fraction Phase 3 2572 Change in NT-proBNP from baseline to week 12 and change in 6 minute walk distance (6MWD) from baseline to Week 24 Sacubitril/valsartan 50 mg, 100 mg and 200 mg bid and matching placebo Enalapril 2.5 mg, 5 mg and 10 mg bid and matching placebo Valsartan 40 mg, 80 mg, 160 mg bid and matching placebo Heart failure patients (NYHA Class II-IV) with preserved ejection fraction Target Patients Read-out Milesstone(s) 2019 (actual) Publication Primary data publication in High Tier Journal 2021 NCT03785405 (CLCZ696B2319E1 - extension study) Heart failure in pediatric patients Phase 3 240 Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Single arm, open label sacubitril/valsartan (pediatric formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid)) Pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 2023 TBD 60 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#61Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD KJX839 - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03060577 ORION-3 (CKJX839A12201E1) Hypercholesterolemia inc. Atherosclerotic Cardiovascular Disease (ASCVD) and ASCVD risk equivalents Heterozygous Familial Hypercholesterolaemia (HeFH) Phase 2 490 LDL-C reduction at Day 210 for Group 1 subjects Changes in other lipids and lipoproteins and reduction of LDL-C of more than 50% for patients that are above LDL-C goal; longer term exposure and safety. Group 1 - inclisiran sodium 300mg sc on Day 1 and every 180 days thereafter for up to 4 years. Group 2- Evolocumab 140mg s.c. injection on Day 1 and every 2 weeks until Day 336, followed by inclisiran 300mg on Day 360, Day 450 and then every 6 months for a planned duration of 4 years. Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy Target Patients Read-out Milesstone(s) Publication 2022 TBD NCT03705234 ORION-4 (CKJX839B12301) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) Phase 3 15000 A composite of major adverse cardiovascular events, defined as: Coronary heart disease (CHD) death; Myocardial infarction; Fatal or non-fatal ischaemic stroke; or Urgent coronary revascularization procedure Arm 1: every 6 month treatment KJX839 300mg (given by subcutaneous injection on the day of randomization, at 3 months and then every 6- months) for a planned median duration of about 5 years Arm 2: matching placebo (given bysubcutaneous injection on the day of randomization, at 3 months and then every 6- months) for a planned median duration of about 5 years. Patient population with mean baseline LDL-C ≥ 100mg/dL 2026 TBD 61 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#62Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD KJX839 - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03814187 ORION-8 (CKJX839A12305B) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 2'991 Proportion of subjects achieving prespecified low density lipoprotein cholesterol (LDL-C) targets at end of study Safety and tolerability profile of long term use of inclisiran Inclisiran sodium 300mg on day 1 (placebo patients entered into study from ORION 9, 10 & 11) or placebo on Day 1 (inclisiran patients entered into study from ORION 9, 10 & 11) then inclisiran 300mg on Day 90 and every 6 months for a planned duation of 3 years Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy and risk equivalents (patients from ORION 9, 10 & 11 studies) Read-out Milesstone(s) 2023 Publication TBD NCT03851705 ORION-5 (CKJX839A12302) Hypercholesterolemia inc. Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 56 LDL-C reduction at Day 150 Changes in PCSK9, other lipids and lipoproteins Part 1: inclisiran sodium 300mg on Day 1 and Day 90 or placebo on Day 1 and Day 90 Part 2: inclisiran on Day 180 for patients who were randomized to the placebo group only, inclisiran on Day 270 and then every 6 months for a planned duration of 2 years for all patients Patients with HoFH with background statin +/- ezetimibe therapy Primary: Q3-2020 (actual); Final: H2-2021 TBD 62 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#63Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD KJX839 - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures NCT04652726 ORION-16 (CKJX839C12301) Hyperlipidemia, pediatrics Phase 3 150 Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Arms Intervention NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Phase 3 15 Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630; Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630; Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL- Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL- Target Patients C) Read-out Milesstone(s) Publication 2023 TBD 63 Investor Relations | Q2 2021 Results 2023 TBD 1 NOVARTIS | Reimagining Medicine#64Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LNP023 - Factor B inhibition of the complement alternative pathway Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03373461 (CLNP023X2203) IgA nephropathy (IgAN) Phase 2 112 Change from baseline of log transformed UPCR derived from the 24h urine collections at Baseline and Day 90 Placebo LNP023 Dose 1 LNP023 Dose 2 LNP023 Dose 3 LNP023 Dose 4 NCT03439839 (CLNP023X2201) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 16 Reduction of chronic hemolysis, based on LDH level at Week 13 10 patients receiving LNP023 high dose daily over up to approximately 3 years 5 patients receiving LNP023 low dose daily over up to approximately 3 years Target Patients Read-out Milesstone(s) Publication Patients with biopsy-verified IgA nephropathy H1-2021 (actual) Barratt et al. 2021. Oral Presentation at the 58th ERA-EDTA congress (Late Breaking Clinical Trials), June 6: IA2 results. Patients with PNH, showing signs of active hemolysis despite treatment with SoC (defined as an antibody with anti C5 activity). Primary: Q2-2020 (actual) Extension: 2023 Antonio M. Risitano, MD, PhD1 et al. Presented at EBMT 2020 congress Jan 2021Pubs: Lancet Haematol - Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 64 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#65Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LNP023 - Factor B inhibition of the complement alternative pathway Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03832114 (CLNP023X2202) C3 glomerulopathy (C3G) Phase 2 27 Cohort A: Ratio to Baseline of UPCR to Week 12 derived from 24hr urine collection Cohort B: Change from Baseline in C3 Deposit Score (based on immunofluorescence microscopy) at Week 12 Increasing doses of LNP023 up to 200mg bid: Cohort A: Native kidney patients Cohort B: Kidney transplanted patients Patients with C3 glomerulopathy H1-2021 (interim actual) Actual: Interim analysis data from Cohort-A presented at American Society of Nephrology (ASN 2020). Planned: Note not to be communicated externally until accepted. 1) Planned abstract at ERA-EDTA, Q3 2021 2) Planned abstract at ASN, Q4 2021 NCT03896152 (CLNP023X2204) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 13 Reduction of PNH associated hemolysis, based on percentage of patients with 60% reduction in LDH or LDH below upper limit of normal up to 12 weeks of treatment. approximately 2 year Treatment with low LNP023 dose approximately 2 year Treatment with higher LNP023 dose Patients with PNH, showing signs of active hemolysis, not treated with any other complement inhibitor less than 3 months prior to study start Day 1 Primary: Q2-2020 (actual) Extension: 2022 -Jang JH, et al. Presented at Korean Society of Hematology International Conference and 62nd Annual Meeting (ICKSH 2021) -Presented as an oral presentation (encore) at the European Haematology Association (EHA 2021) congress -Planned manuscript submission in Q3 2021 65 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#66Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LNP023 - Factor B inhibition of the complement alternative pathway Study Indication Phase Patients Primary Outcome Measures NCT03955445 (CLNP023B12001B) C3 glomerulopathy (C3G) Phase 2 27 Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Arms Intervention Open-label LNP023 200mg bid NCT04154787 (CLNP023D12201) Idiopathic membranous nephropathy (IMN) Phase 2 72 Change from baseline of UPCR derived from 24hr urine collections at Baseline and Week 24 LNP023 low dose LNP023 high dose Rituximab Patients with biopsy proven iMN who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria 2023 Target Patients Patients with C3 glomerulopathy Read-out Milesstone(s) Publication 2025 Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory TBD 66 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#67Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LNP023 - Factor B inhibition of the complement alternative pathway Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04558918 APPLY-PNH (CLNP023C12302) Paroxysmal nocturnal haemoglobinuria Phase 3 91 Percentage of participants achieving a sustained increase in hemoglobin levels of ≥ 2 g/dL in the absence of red blood cell transfusions Percentage of participants achieving sustained hemoglobin levels ≥12 g/dL in the absence of red blood cell transfusions Arm 1: Drug: LNP023, taken orally b.i.d. dosage supplied: 200 mg dosage form: hard gelatin capsule Route of Administration: Oral Arm 2: Drug: Eculizumab, administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose. Dosage supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion Drug: Ravulizumab, administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight. Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion Adult patients with PNH and residual anemia, despite treatment with an intravenous Anti-C5 antibody Primary 2022 TBD NCT04578834 APPLAUSE-IgAN (CLNP023A2301) IgA nephropathy Phase 3 450 Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine collection) at 9 months Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated over 24 months Arm 1 LNP023 200mg BID Arm 2 - Placebo BID Primary IgA Nephropathy patients 2023 Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: Study Design Wong et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY 67 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine#68Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LNP023 - Factor B inhibition of the complement alternative pathway Study Indication Phase Patients Primary Outcome Measures NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 68 Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Arms Intervention Target Patients Experimental: iptacopan 200mg b.i.d. Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Patients with native C3G Read-out Milesstone(s) 2023 Publication TBD 68 Investor Relations | Q2 2021 Results NCT04820530 APPOINT-PNH (CLNP023C12301) Paroxysmal nocturnal haemoglobinuria Phase 3 40 Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥2 g/dL assessed, in the absence of red blood cell transfusions Iptacopan (LNP023), taken orally b.i.d. (dosage supplied: 200mg) PNH patients who are naive to complement inhibitor therapy, including anti-C5 antibody 2023 TBD NOVARTIS | Reimagining Medicine#69Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations TQJ230 - Antisense oligonucleotide targeting apolipoprotein(a) mRNA Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04023552 Lp(a) HORIZON (CTQJ230A12301) Cardiovascular risk reduction Phase 3 7680 Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization) TQJ230 80 mg injected monthly subcutaneously or matched placebo Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL Target Patients Read-out Milesstone(s) 2024 Publication TBD 69 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#70Participants Company overview Pharmaceuticals Oncology Financial performance CRM IHD Neuroscience Oncology Ophthalmology Financial review Conclusion Appendix Innovation: Pipeline overview Immunology, Hepatology & Dermatology 70 Investor Relations | Q2 2021 Results Respiratory References Innovation: Clinical trials Sandoz Biopharmaceuticals Global Health Abbreviations NOVARTIS | Reimagining Medicine#71Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CFZ533 - Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03781414 CONTRAIL I (CCFZ533A2202) Liver transplantation Phase 2 128 Proportion of patients with composite event (BPAR, Graft Loss or Death) over 12 months Control/Standard of Care: TAC + MMF + Corticosteroids CFZ533 dose A+ MMF + Corticosteroids CFZ533 dose B + MMF + Corticosteroids Target Patients Liver transplant recipients Read-out Milesstone(s) 2023 Publication 2023 71 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#72Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CFZ533 - Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03663335 CIRRUS I (CCFZ533A2201) Kidney transplantation Phase 2 325 Proportion of patients with composite event (BPAR, Graft Loss or Death) at M12 Two cohorts: de novo TX and maintenance Test Arms: CFZ533 + MMF + corticosteroids Standard of Care: TAC + MMF + corticosteroids Kidney transplant recipients NCT03905525 TWINSS (CCFZ533B2201) Sjögren's syndrome Phase 2 260 Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score Three dose arms of CFZ533 Placebo Target Patients Read-out Milesstone(s) 2022 Publication 2022 72 Investor Relations | Q2 2021 Results Patients with Sjögren's syndrome 2022 2022 NOVARTIS | Reimagining Medicine#73Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase NCT03031782 (CAIN457F2304) Psoriatic arthritis Phase 3 Patients 80 Primary Outcome Measures Time to 33 flares Arms Intervention Secukinumab (pre-filled syringe) 75 mg Placebo Juvenile idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis Target Patients Read-out Milesstone(s) H1-2021 Publication H2-2021 73 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#74Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03259074 SURPASS (CAIN457K2340) Ankylosing spondylitis Phase 3 837 No radiographic structural progression as measured by modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Secukinumab 150/300 mg Adalimumab biosimilar 40 mg Patients with active ankylosing spondylitis Target Patients Read-out Milesstone(s) 2022 Publication Study design manuscript published. Baraliakos et al. Clinical Drug Investigation (2020) 40:269-278. NCT03504852 (CAIN457A2324) Psoriasis Phase 3B 331 PASI 90 response and IGA mod 2011 0 or 1 response after 16 weeks of treatment Secukinumab 300 mg every 2 weeks after weekly doses till Week 4 Secukinumab 300 mg every 4 weeks after weekly doses till Week 4 Subjects (≥90kg) with moderate to severe plaque psoriasis Q3-2020 (actual) Publication (primary efficacy) in Q3-2021 (ongoing) Publication of 52-week planned in Q4-2021 (planned) Abstract at AAD in Q2-2021 Reich K. et al Presented at 2021 AAD VMX (LBA). Selected to be highlighted in the AAD "Meeting News", 74 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#75Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication 75 Investor Relations | Q2 2021 Results NCT03589885 MATURE (CAIN457A2325) Psoriasis Phase 3 NCT03668613 (CAIN457A2311) Psoriasis Phase 3 122 84 PASI 75 response and IGA mod 2011 0 or 1 response after 12 weeks of treatment Secukinumab 2 mL (300 mg) auto-injector Secukinumab 2 x 1 mL (150 mg each) prefilled syringe Placebo 2 mL auto-injector Placebo 2 x 1 mL prefilled syringe Subjects with moderate to severe plaque psoriasis Final: Q4-2020 Sigurgeirsson et al, Presentation at AAD VMX 2021 (16-week) IFPA 2021 (planned) EADV 2021 (planned) 52-week publication H2-2021 Psoriasis Area and Severity Index (PASI) 75 response and Investigators' Global Assessment (IGA) 0 or 1 response at week 12 Secukinumab low dose Secukinumab high dose Pediatric patients of age 6 to <18 years, with moderate to severe plaque psoriasis 2023 24-week paper publication in Q3 2021 (estimate). Magnolo et al. Presentation at AAD VMX 2021. Magnolo et al. Presentation at ESPD 2021. SPD (Q3 2021 - planned) EADV (Q3 2021 - planned) - pooled A2310/A2311 PG2C (Q4 2021 - planned) - pooled A2310/A2311 1 NOVARTIS | Reimagining Medicine#76Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03713619 SUNSHINE (CAIN457M2301) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of participants with Hidradenitis Suppurativa clinical response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Patients with moderate to severe Hidradenitis Suppurativa Read-out Milesstone(s) Primary (week 16): H2-2021; Final: 2022 Publication Study design SHSA 2020; Primary 2022 NCT03713632 SUNRISE (CAIN457M2302) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Subjects with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: 2022 Study design SHSA 2020; Primary 2022 76 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#77Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03769168 (CAIN457F2304E1 - extension study) Psoriatic arthritis Phase 3 64 Number of participants with JIA ACR30 response Secukinumab 75 mg/0.5 ml Secukinumab 150 mg/1.0 ml Patients with juvenile idiopathic arthritis subtypes of juvenile psoriatic arthritis and enthesitis related arthritis Target Patients Read-out Milesstone(s) 2025 Publication TBD NCT04156620 INVIGORATE-1 (CAIN457P12301) Axial spondyloarthritis Phase 3 500 The proportion of subjects achieving an ASAS40 (Assessment of SpondyloArthritis International Society criteria) response Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active axial spondyloarthritis Primary (week 16): 2022; Final: 2023 2023 77 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#78Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase Patients Primary Outcome Measures NCT04179175 (CAIN457M2301E1) Hidradenitis Suppurativa (HS) Phase 3 745 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Arms Intervention Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Patients with moderate to severe hidradenitis suppurativa completing either of the core trials AIN457M2301 (NCT 0313632) or AIN567M2302 (NCT03713619) Target Patients Read-out Milesstone(s) 2025 Publication Study design SHSA 2020 NCT04181762 SELUNE (CAIN457Q12301) Lupus Nephritis Phase 3 460 Proportion of subjects achieving protocol-defined CRR Secukinumab 300 mg s.c. Placebo s.c. Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co- existing class V features) 2026 2026 78 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#79Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04209205 INVIGORATE-2 (CAIN457P12302) Psoriatic Arthritis (PSA) Phase 3 380 The proportion of subjects achieving American College of Rheumatology 50 (ACR50) response criteria Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active psoriatic arthritis (PSA) despite current or previous NSAID, DMARD and/or anti-TNF therapy Target Patients Read-out Milesstone(s) 2022 Publication 2023 NCT04300296 PRELUDE (CAIN457S12201) Lichen Planus Phase 2 108 Proportion of patients achieving Investigator's Global Assessment (IGA 0/1) score at 16 weeks +30% delta vs placebo Secukinumab 300 mg s.c. Placebo s.c. Adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies 2022 TBD 79 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#80Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LJN452 - FXR Agonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04065841 ELIVATE (CLJN452D12201C) Non-alcoholic steatohepatitis (NASH) Phase 2 380 Proportion of patients with resolution of NASH and no worsening of fibrosis OR improvement in fibrosis by at least one stage without worsening of NASH at Week 48 compared with baseline Arm A: combination therapytropifexor + licogliflozin Arm B: tropifexor monotherapytropifexor + licogliflozin placebo Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo Arm D: licogliflozin placebo + tropifexor placebo Adult patients with biopsy based non-alcoholic steatohepatitis (NASH) and liver fibrosis Target Patients Read-out Milesstone(s) Publication 2023 2023 80 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#81Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD LNA043 - ANGPTL3 Agonist Study Indication Phase Patients Primary Outcome Measures NCT03275064 (CLNA043X2202) Knee osteoarthritis Phase 2 133 Articular cartilage bi-layer collagen organisation evaluated with MRI and measured in milliseconds (ms) (Part A only) Number of patients with any adverse events, serious adverse events and death (Part A and Part B) Change in cartilage volume/thickness in the index region (Part B only) NCT04864392 ONWARDS (CLNA043A12202) Knee osteoarthritis Phase 2 550 Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging Arms Intervention LNA043 40 mg Part B LNA043 20 mg Part B LNA043 20 mg Part A Placebo Part A Placebo Part B Patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B) LNA043 injection to the knee with dosing regimen A LNA043 injection to the knee with dosing regimen B LNA043 injection to the knee with dosing regimen C LNA043 injection to the knee with dosing regimen D Placebo injection to the knee Patients with Symptomatic knee osteoarthritis Target Patients Read-out Milesstone(s) 2022 Publication 81 Investor Relations | Q2 2021 Results TBD Primary 2024 TBD 1 NOVARTIS | Reimagining Medicine#82Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LOU064 - Bruton's tyrosine kinase (BTK) inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03926611 (CLOU064A2201) Chronic spontaneous urticaria (CSU) Phase 2 308 Change from baseline in weekly Urticaria Activity Score (UAS7) at Week 4 Arm 1 Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 2 Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 3 High dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 4 Low dose of LOU064 orally, twice daily from Day 1 to 85 Arm 5 Medium dose of LOU064 orally, twice daily from Day 1 to 85 Arm 6 High dose of LOU064 orally, twice daily from Day 1 to 85 Placebo arm Matching placebo, orally, twice daily from Day 1 to 85 Adults with CSU inadequately controlled by H1-antihistamines H2-2021 Target Patients Read-out Milesstone(s) Publication H2-2021 NCT04109313 (CLOU064A2201E1) Chronic spontaneous urticaria (CSU) Phase 2 250 Long-term safety and tolerability Selected dose of LOU064 taken orally twice a day (morning and evening) from day 1 to week 52 Patients with CSU who have participated in preceding studies with LOU064 2022 TBD 82 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine#83Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations QGE031 - Anti-IgE Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04210843 (CQGE031C2302E1) Chronic spontaneous urticaria Phase 3 800 The proportion of subjects with well-controlled disease (UAS7 ≤ 6) at week 12 Ligelizumab Dose 1 and 3 Ligelizumab Dose 2 and 3 Patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 Read-out Milesstone(s) 2026 Publication Study design presented at 2020 EAACI NCT02649218 (CQGE031C2201E1) Chronic spontaneous urticaria Phase 2 226 Long-term safety; number of participants with treatment-emergent adverse events Ligelizumab 240 mg q4wks open label for 52 weeks Adult patients with chronic spontaneous urticaria inadequately controlled with H1- antihistamines at approved or increased doses, alone or in combination with H2- antihistamines or leukotriene receptor antagonists. 2019 (actual) Manuscript: Primary results extension trial (JAMA), H2 2021 83 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#84Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations QGE031 - Anti-IgE Study Indication Phase NCT03580356 PEARL 2 (CQGE031C2303) Chronic spontaneous urticaria Phase 3 Patients Primary Outcome 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Measures Arms Intervention Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Target Patients Read-out Milesstone(s) Publication Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 NCT03580369 PEARL 1 (CQGE031C2302) Chronic spontaneous urticaria Phase 3 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 84 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#85Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations VAY736 - BAFF-R inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03217422 AMBER (CVAY736B2201) Autoimmune hepatitis Phase 2 80 Alanine aminotransferase (ALT) normalization Arms Intervention VAY736 Placebo control with conversion to active VAY736 Autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care Target Patients Read-out Milesstone(s) 2026 Publication TBD 85 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#86Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Neuroscience 86 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#87Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations AimovigⓇ - CGRP receptor antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03867201 DRAGON (CAMG334A2304) Migraine Phase 3 550 Change from baseline in monthly migraine days during the last 4 weeks of the 12- week treatment period Subcutaneous injection of AMG334 (erenumab) 70 mg Subcutaneous injection of placebo Adult chronic migraine patients Double-blind FIR for 100% of pts 2021; Q4 2021 Extension (open-label): 2024 Planned in H2-2022 for double-blind phase and H1-2025 for open-label extension phase 87 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#88Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LMI070 - SMN2 RNA splice modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT02268552 (CLMI070X2201) Type 1 spinal muscular atrophy Phase 1/2 39 Number of participants with adverse events (AEs) and serious adverse events (SAEs) Branaplam oral, once weekly: Part 1: 5 ascending doses Part 2: 2 different dose levels Part 3: patients continue on initial dose assigned in Part 1 or Part 2 Patients with type 1 spinal muscular atrophy Study Part 2: Q3-2020 (actual) Study Part 3: 2023 Publication 88 Investor Relations | Q2 2021 Results TBD NOVARTIS | Reimagining Medicine#89Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations MIJ821 - NR2B negative allosteric modulator (NAM) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04722666 (CMIJ821A12201) Depression (Major Depressive Disorder) Phase 2 195 Change from baseline to 24 hours in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS) MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride for 40 minutes IV infusion MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride for 40 minutes IV infusion Participants with major depressive disorder who have suicidal ideation with intent Target Patients Read-out Milesstone(s) 2023 Publication TBD 89 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#90Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations OMB157 - Anti-CD20 Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03650114 ALITHIOS (COMB157G2399) Multiple Sclerosis Phase 3 2010 Evaluate the long-term safety and tolerability of ofatumumab 20 mg subcutaneous (sc) once every 4 (94) weeks in subjects with RMS from the first dose of ofatumumab Ofatumumab 20 mg every 4 weeks Patients with relapsing MS Target Patients Read-out Milesstone(s) Publication 2028 TBD 90 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#91Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03381729 STRONG (CL-102) Type 2 spinal muscular atrophy Phase 1 51 Safety and tolerability, incidence of adverse events Proportion of patients achieving Standing Milestone Change in Hammersmith Functional Motor Scale Open-label, single-arm, single-dose, intrathecal Patients with spinal muscular atrophy with 3 copies of SMN2 Cohort B: Q4-2019 (actual); Cohort C1: TBC Read-out Milesstone(s) Publication TBD NCT03837184 STRIVE Asia Pacific (CL-306) Type 1 spinal muscular atrophy Phase 3 2 Proportion of participants sitting without support Open-label, single-arm, single-dose, intravenous Patients with spinal muscular atrophy Type 1 H2-2021 TBD 91 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#92Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03505099 SPR1NT (CL-304) Spinal muscular atrophy Phase 3 30 [2 copies of SMN2] Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit [3 copies of SMN2] Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit Open-label, single-arm, single-dose, intravenous Pre-symptomatic patients with spinal muscular atrophy and multiple copies SMN2 H2-2021 (3-copy cohort) Final study results of 2-copy cohort as late-breaker oral presentation at EAN Jun 22 2021 92 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#93Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Oncology 93 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#94Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Innovation: Clinical trials Abbreviations 177Lu-PSMA-617- Radioligand therapy targeting prostate specific membrane antigen (PSMA) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03511664 VISION (PSMA-617-01) PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) Phase 3 831 Radiographic Progression Free Survival Overall Survival 177Lu-PSMA-617 plus BS/BSC BS/BSC alone Adult patients with PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) Primary Analysis: Mar-2021 (Actual) Final Analysis: Q4-2022 Morris et al. Presented at ASCO (6-Jun-2021) Manuscript e-publication expected Jun-2021 94 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#95Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations 177Lu-PSMA-617 - Radioligand therapy target PSMA Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT04689828 PSMAfore (CAAA617B12302) Metastatic castration-resistant prostate cancer, pre-taxane Phase 3 495 Radiographic Progression Free Survival (rPFS) Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings Primary Analysis: 2022 Final Analysis: 2025 NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Phase 3 1126 Radiographic Progression Free Survival (rPFS) Arm 1: 177Lu-PSMA-617 Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA- 617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Final Analysis: 2024 Publication 95 Investor Relations | Q2 2021 Results TBD TBD NOVARTIS | Reimagining Medicine#96Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ABL001 - Specific, allosteric Bcr-Abl kinase inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03106779 ASCEMBL (CABL001A2301) Chronic myeloid leukaemia (CML) Phase 3 233 Major Molecular Response (MMR) rate at 24 weeks ABL001 40 mg bid Bosutinib 500 mg Patients with chronic myelogenous leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors Q3-2020 (actual) Hochhaus A., et al. [Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs), LBA-4] ASH 2020 Manuscript submission H1-2021 96 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#97Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD ACZ885-IL-1 beta inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03447769 CANOPY-A (CACZ885T2301) Adjuvant NSCLC Phase 3 1500 Disease free survival (primary), overall survival (key secondary) Canakinumab 200mg q3w sc for 18 cycles Placebo q3w sc for 18 cycles Patients with: High-risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB (T>5cm N2)) after complete resection and standard of care adjuvant cisplatin-based chemotherapy All histologies Read-out Milesstone(s) 2023 Publication TBD NCT03626545 CANOPY-2 (CACZ885V2301) 2nd/3rd Line Non-small cell lung cancer (NSCLC) Phase 3 240 Safety run-in part: Incidence of dose limiting toxicities Double-blind, randomized, placebo-controlled part: Overall Survival Canakinumab in combination with docetaxel Canakinumab matching-placebo in combination with docetaxel Patients with: Stage IIIB or IV NSCLC without EGFR, ALK, ROS-1 or B-RAF mutation Previously treated with platinum therapy and PD(L)1-inhibitor March-2021 (Actual) Abstract submitted to ESMO, manuscript in progress. 97 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#98Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD ACZ885-IL-1 beta inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03631199 CANOPY-1 (CACZ885U2301) 1st Line Non-small cell lung cancer (NSCLC) Phase 3 627 Safety run-in part: Incidence of dose limiting toxicities Double-blind, randomized, placebo-controlled part: Progression free survival (PFS) Overall survival (OS) Canakinumab or matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy Patients with Histologically confirmed Stage IIIB, IV NSCLC with no prior systemic anticancer therapy Squamous and non-squamous NSCLC No EGFR mutation and ALK rearrangement H2-2021 Johnson B et al. Presented at AACR-NCI-EORTC 2019 (safety run-in) Planned abstract submission to congress in 2H 2021 98 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#99Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BYL719 - Alpha-specific PI3K inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04208178 EPIK-B2 (CBYL719G12301) HER-2 positive breast cancer Phase 3 548 Progression-free survival (PFS) Alpelisib + trastuzumab + pertuzumab Trastuzumab + pertuzumab Patients with HER2-positive advanced breast cancer with a PIK3CA mutation Read-out Milesstone(s) 2025 Publication TBD NCT04251533 EPIK-B3 (CBYL719H12301) Triple negative breast cancer Phase 3 566 Progression-free Survival (PFS) for patients with PIK3CA mutant status Alpelisib 300 mg + nab-paclitaxel 100 mg/m² Placebo nab-paclitaxel 100 mg/m² Patients with advanced triple negative breast cancer with either Phosphoinositide-3- kinase Catalytic Subunit Alpha (PIK3CA) mutation or Phosphatase and Tensin Homolog Protein (PTEN) loss without PIK3CA mutation 2023 TBD 99 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#100Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BYL719 - Alpha-specific PI3K inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04589650 EPIK-P2 (CBYL719F12201) PIK3CA-related overgrowth spectrum Phase 2 150 Proportion of participants with a response at Week 24 Arm 1: alpelisib vs. Arm 2: placebo during the 16 first weeks. for each cohort (adult, pediatric) Pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS) Primary Analysis: H1-2023 NA 100 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#101Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations JakaviⓇ - JAK1/2 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03491215 REACH4 (CINC424F12201) Acute graft versus host disease Phase 2 45 Measurement of PK parameters Overall Response Rate (ORR) Ruxolitinib NCT03774082 REACH5 (CINC424G12201) Chronic graft versus host disease Phase 2 42 Overall Response Rate (ORR) Ruxolitinib 5mg tablets / pediatric formulation Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantation Pediatric subjects with moderate and severe chronic Graft vs. Host disease after allogeneic stem cell transplantation Target Patients Read-out Milesstone(s) 2023 Publication TBD 101 Investor Relations | Q2 2021 Results 2023 TBD NOVARTIS | Reimagining Medicine#102Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations JakaviⓇ - JAK1/2 inhibitor Study Indication Phase Patients NCT04097821 ADORE (CINC424H12201) Myelofibrosis Phase 1/2 130 Primary Outcome Measures Arms Intervention Incidence of dose limiting toxicities within the first 2 cycles Response rate at the end of cycle 6 Ruxolitinib Ruxolitinib+Siremadlin Ruxolitinib+Crizanlizumab Ruxolitinib+MBG453 Ruxolitinib+LTT462 Ruxolitinib+NIS793 Patients with Myelofibrosis (MF) Target Patients Read-out Milesstone(s) Publication 2024 TBD 102 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#103Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Kisqali® - CDK 4/6 inhibitor Study Indication NCT03701334 NATALEE (CLEE011012301C) Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC) Phase 3 Phase Patients Primary Outcome Measures Arms Intervention Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions for Efficacy End Points in adjuvant breast cancer trials) Ribociclib endocrine therapy Endocrine therapy Pre and postmenopausal women and men with HR-positive, HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy Target Patients Read-out Milesstone(s) 2022 Publication TBD 103 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#104Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Piqray® - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04729387 EPIK-O (CBYL719K12301) Ovarian Cancer Phase 3 Progression Free Survival (PFS) based on Blinded Independent Review Committee (BIRC) assessment using RECIST 1.1 criteria Arm 1 Experimental: Alpelisib+olaparib: Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule Arm 2 Active Comparator: Paclitaxel or PLD. Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days. Patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected Read-out Milesstone(s) 2023 Publication TBD 104 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#105Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations KymriahⓇ - CAR-T therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03568461 ELARA (CCTL019E2202) Relapsed/refractory follicular lymphoma (FL) Phase 2 97 Complete Response Rate (CRR) Single-arm study of tisagenlecleucel Adult patients with relapsed or refractory FL H1-2021 (actual) Schuster, et al. presented at ASCO, EHA and ICML 2021 NCT03570892 BELINDA (CCTL019H2301) 2nd line Diffuse large B-cell lymphoma (DLBCL) Phase 3 318 Event-free Survival (EFS) Tisagenlecleucel versus standard of care Adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline- containing frontline immunochemotherapy H2-2021 Bishop et al at SITC 2019 Abstract submission to congress in H2-2021 105 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#106Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations KymriahⓇ - CAR-T therapy Study Indication Phase Patients Primary Outcome Measures NCT03876769 CASSIOPEIA (CCTL019G2201J) 1st line high risk acute lymphoblastic leukemia (ALL) Phase 2 160 Disease Free Survival (DFS) Single-arm study of tisagenlecleucel Pediatric and young adult patients with 1st line high risk ALL Arms Intervention Target Patients Read-out Milesstone(s) 2025 Publication TBD 106 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#107Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations MBG453 - TIM-3 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT03946670 STIMULUS MDS-1 (CMBG453B12201) Myelodysplastic syndrome Phase 2 120 Complete Remission (CR) rate and Progression Free Survival (PFS) Experimental: Sabatolimab (MBG453) + hypomethylating agents Placebo comparator: Placebo + hypomethylating agents Adult subjects with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as per IPSS-R criteria 2022-2023 NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Myelodysplastic syndrome Phase 3 500 Overall survival Sabatolimab 800 mg + azacitidine 75 mg/m2 Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) 2023 Publication TBD 107 Investor Relations | Q2 2021 Results TBD NOVARTIS | Reimagining Medicine#108Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations MBG453 - TIM-3 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04150029 STIMULUS-AML1 (CMBG453C12201) Unfit acute myeloid leukaemia Phase 2 86 Incidence of dose limiting toxicities (Safety run-in patients only) Percentage of subjects achieving complete remission (CR) Single arm safety and efficacy study of sabatolimab in combination with azacitidine and venetoclax Target Patients Newly diagnosed adult AML patients who are not suitable for treatment with intensive chemotherapy Read-out Milesstone(s) 2023 Publication TBD 108 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#109Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations NIS793 - TGFẞ1 inhibitor Study Indication Phase Patients Primary Outcome Measures NCT02947165 (CNIS793X2101) Solid tumors Phase 1 120 Incidence of DLTS, AES, SAEs and dose reductions / interruptions for NIS793 Incidence of DLTS, AES, SAES and dose reductions/interruptions for NIS793 in combination with PDR001 Arms Intervention NIS793 NIS793 + PDR001 Adult patients with advanced malignancies Target Patients Read-out Milesstone(s) Publication 2021 TBD 109 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#110Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations PDR001 - PD-1 checkpoint inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03484923 (CPDR001J2201) Previously treated unresectable or metastatic melanoma Phase 2 195 Objective Response Rate (ORR) Spartalizumab (PDR001) 400mg i.v. Q4W + LAG525 (to be tested in unselected patients and LAG-3 positive patients) Spartalizumab 400mg i.v. Q4W + capmatinib Spartalizumab 400mg i.v. Q4W + canakinumab Spartalizumab 400mg i.v. Q4W + ribociclib Adult patients with previously treated unresectable or metastatic melanoma Target Patients Read-out Milesstone(s) Publication 2022 TBD 110 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#111Participants Company overview Pharmaceuticals Oncology Financial performance CRM IHD Neuroscience Oncology Ophthalmology Financial review Conclusion Appendix Innovation: Pipeline overview Respiratory References Innovation: Clinical trials Abbreviations Sandoz Biopharmaceuticals Global Health PromactaⓇ/Revolade® - Thrombopoetin receptor agonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT03025698 (CETB115E2201) Previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia Phase 2 60 PK of eltrombopag at steady state in pediatric patients with SAA Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent AA after IST or previously untreated SAA Primary CSR: 2022 Final CSR: 2025 NCT03988608 (CETB115E2202) Previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia Phase 2 20 Hematologic response rate rate up to 26 weeks of treatment Eltrombopag 25 mg film-coated tablets Chinese patients with refractory or relapsed severe aplastic anemia Primary: 2021; Final: 2023 Publication TBD 111 Investor Relations | Q2 2021 Results TBD 1 NOVARTIS | Reimagining Medicine#112Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations RydaptⓇ - Multi-targeted kinase inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03591510 (CPKC412A2218) Acute myeloid leukemia Phase 2 50 Occurrence of dose limiting toxicities Event Free Survival (EFS) Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Target Patients Read-out Milesstone(s) 2025 Publication TBD 112 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#113Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD SEG101 - P-Selectin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of VOC in pediatric patients with SCD Phase 2 100 PK/PD and safety of SEG101 at 5 mg/kg SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion + Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients ≥12 year old) NCT03814746 STAND (CSEG101A2301) Prevention of Vaso-Occlusive Crises (VOC) in patients with Sickle Cell Disease (SCD) Phase 3 240 Rate of VOC events leading to healthcare visit Crizanlizumab 5.0 mg/kg Crizanlizumab 7.5 mg/kg Placebo Adolescent and adult SCD patients (12 years and older) 2022 Publication 2024 (pediatric patients <12 year old) Planned abstract submission to congress in H2-2021 TBD 113 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#114Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD TabrectaⓇ - Met Inhibitor Study Indication Phase Patients Primary Outcome Measures NCT04427072 (CINC280A2301) Non-small cell lung cancer Phase 3 90 Progression free survival (PFS) per blinded independent review committee (BIRC) using RECIST v1.1 Arms Intervention Target Patients Read-out Milesstone(s) Arm 1: 400mg of capmatinib tablets administered orally twice daily Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 days Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METAex14). Primary 2022 Final: 2024 Publication TBD 114 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#115Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Tafinlar® - BRAF inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT01677741 (CDRB436A2102) BRAFV600 mutant cancers Phase 1/2 85 Safety, tolerability and pharmacokinetics Single-arm study of oral dabrafenib (dose based on age and weight) Pediatric subjects aged 1 year to <18 years with advanced BRAF V600-mutation positive solid tumors H1-2021 (actual) Kieran MW et al. Clin Cancer Res 2019;25(24):7294-7302 (PK analysis) Hargrave DR et al. Clin Cancer Res 2019;25(24):7303-7311 (safety/efficacy in low- grade gliomas) 115 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#116Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Tafinlar®+Mekinist® - BRAF inhibitor and MEK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT02684058 (CDRB436G2201) BRAFV600 mutant gliomas Phase 2 142 Objective response rate Dabrafenib + trametinib (dose based on age and weight) Children and adolescent patients with BRAF V600 mutation positive relapsed or refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade glioma (LGG) Read-out Milesstone(s) 2022 Publication TBD 116 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#117Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations TNO155 - SHP2 Inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03114319 (CTNO155X2101) Solid tumors (single agent) Phase 1 255 Number of participants with adverse events Number of participants with dose limiting toxicities Arms Intervention Drug: TNO155 Drug: TNO155 in combination with EGF816 (nazartinib) Adult patients with advanced solid tumors in selected indications NCT04000529 (CTNO155B12101) Solid tumors (combo) Phase 1 126 Incidence of dose limiting toxicities (DLTs) during the first cycle of combination treatment during the dose escalation part Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment Dose tolerability TNO155 and Spartalizumab (PDR001) TNO155 and Ribociclib (LEE011) Patients with advanced malignancies Target Patients Read-out Milesstone(s) 2023 Publication TBD 117 Investor Relations | Q2 2021 Results 2022 TBD NOVARTIS | Reimagining Medicine#118Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Ophthalmology 118 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#119Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03386474 (CRTH258A2301E1) Neovascular age-related macular degeneration (nAMD) Phase 3 150 Number of treatment-emergent adverse events Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study Target Patients Read-out Milesstone(s) 2018 (actual) Publication Planned publication of the attributes of brolucizumab and durability in H1-2021 NCT03481634 KESTREL (CRTH258B2301) Diabetic eye disease Phase 3 534 Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 3 mg/50 μL Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2mg/50 uL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q4-2020 (actual); Final: H2-2021 Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 119 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#120Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03481660 KITE (CRTH258B2302) Diabetic eye disease Phase 3 356 Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q3-2020 (actual); Final: H2-2021 Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 NCT03917472 KINGFISHER (CRTH258B2305) Diabetic macular edema Phase 3 500 Change in best-corrected visual acuity (BCVA) from baseline up to week 52 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with visual impairment due to diabetic macular edema H2-2021 TBC 120 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#121Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04005352 TALON (CRTH258A2303) Neovascular Age-related Macular Degeneration (nAMD) Phase 3B Average change in Best-corrected visual acuity Distribution of the last interval with no disease activity (in a Treat-to-Control regimen) Arm 1: Brolucizumab 6 mg intravitreal injection Arm 2: Aflibercept 2 mg intravitreal injection Patients with Neovascular Age-related Macular Degeneration (nAMD) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment Target Patients Read-out Milesstone(s) 2022 Publication TBD NCT04047472 HOBBY (CRTH258A2307) Macular degeneration Phase 3 494 Change from baseline in best-corrected visual acuity (BCVA) at week 48 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with neovascular age-related macular degeneration 2024 TBD 121 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#122Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04058067 KINGLET (CRTH258B2304) Diabetic macular edema Phase 3 268 Change in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL NCT04278417 (CRTH258D2301) Diabetic retinopathy Phase 3 706 Change from Baseline in BCVA Arm 1: RTH258 (Brolucizumab) 6 mg3 x q6w loading injections, followed by q12w maintenance through week 90 Arm 2: Panretinal photocoagulation laser initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed Chinese patients with visual impairment due to diabetic macular edema Target Patients Read-out Milesstone(s) Publication 2023 Publication planned for 2023 122 Investor Relations | Q2 2021 Results Patients with proliferative diabetic retinopathy 2024 TBD NOVARTIS | Reimagining Medicine#123Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ECF843-rh-Lubricin Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04391894 (CECF843A2201) Dry eye Phase 2 680 Change from baseline in symptom assessment in Dry Eye (SANDE) score Change from baseline in composite corneal fluorescein staining score A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects with dry eye disease ECF843 0.15 or 0.45 mg/mL BID/TID/vehicle Patients with moderate to severe dry eye disease (DED) Target Patients Read-out Milesstone(s) Publication TBD H2-2021 (actual) 123 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#124Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LucentisⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT02640664 RAINBOW Extension (CRFB002H2301E1) Retinopathy of Prematurity (ROP) Phase 3 180 To evaluate the visual function of patients by assessing the visual acuity in the better-seeing eye at the patient's fifth birthday. Ranibizumab 0.2 mg (up to Week 40, if warranted) Ranibizumab 0.1 mg (up to Week 40, if warranted) Male and female preterm infants with bilateral retinopathy of prematurity (ROP) who completed RAINBOW. Target Patients Read-out Milesstone(s) 2023 Publication TBD 124 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#125Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations SAF312 - TRPV1 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04630158 SAHARA (CSAF312B12201) Chronic ocular surface pain Phase 2 150 Change in mean pain severity Visual Analog Scale Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops, twice daily Subjects with CICP persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. Target Patients Read-out Milesstone(s) Publication 2022 TBD 125 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#126Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations UNR844 - Reduction of disulfide bonds Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) READER (CUNR844A2022) Presbyopia Phase 2B 225 Characterize the dose response relationship among UNR844 doses 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily after Month 3 of dosing. Change from baseline in Binocular distance-corrected near visual acuity at 40 cm at Month 3. 1:1 randomization - UNR844 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily for three months Presbyopic participants aged 45 to 55 years Q3 2022: Interim analysis (Primary endpoint) - when all patients have completed the 3 months treatment period Q4 2022: Interim analysis - when 60% of patients have completed 6 months of post treatment follow-up Q2 2023: Final analysis -Study completion (all patients have completed 9 months pots treatment period) Publication TBD 126 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#127Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Respiratory 127 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#128Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CSJ117 - TSLP inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04410523 (CCSJ117A12201C) Asthma Phase 2 625 Pre-dose FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment. Average change from baseline in pre-dose FEV1 at week 8 & week 12 CSJ117 0.5mg CSJ117 1mg CSJ117 2 mg CSJ117 4 mg CSJ117 8 mg Placebo Asthma patients on background medium or high ICS plus LABA therapy Target Patients Read-out Milesstone(s) 2022 Publication Primary publications planned for 2022 128 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#129Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations QBW251 - CFTR potentiator Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04072887 (CQBW251B2201) Chronic obstructive pulmonary disease (COPD) Phase 2 956 Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment QBW251 450 mg Target Patients QBW251 300 mg QBW251 150 mg QBW251 75 mg QBW251 25 mg Placebo COPD patients on background triple inhaled therapy (LABA / LAMA / ICS) Read-out Milesstone(s) Publication H1-2022 Primary publications planned for 2022 129 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#130Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Sandoz Biopharmaceuticals 130 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#131Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations GP2411 - Biosimilar denosumab Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03974100 (CGP24112301) Osteoporosis Phase 3 522 Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milesstone(s) 2022 Publication Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 131 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#132Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Global Health 132 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#133Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations KAF156 - Plasmodium Falciparum Inhibitor - PfCARL mediated Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03167242 (CKAF156A2202) Malaria Phase 2 PCR-corrected adequate clinical and parasitological response (ACPR) KAF156 and LUM-SDF (different combinations) Coartem Adults and children with uncomplicated Plasmodium Falciparum Malaria H2-2021 Two posters accepted, ASTMH meeting Nov 15-19 2020 Kublin JG et al. Clinical Infectious Diseases 09 Jul 2020, PMID: 32644127 133 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#134Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD artemether + lumefantrine Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04300309 CALINA (CCOA566B2307) Malaria, uncomplicated (<5kg patients) Phase 3 Artemether Cmax - PGH-1 Target Patients Read-out Milesstone(s) Experimental: artemether lumefantrine (2.5 mg:30 mg) artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium falciparum malaria Primary outcome measure: 2023 Publication TBD 134 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#135Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ganaplacide - Imidazolopiperazines derivative Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04546633 KALUMI (CKAF156A2203) Malaria, uncomplicated Phase 2 PCR-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition Malaria patients 12 to < 18 years old with malaria caused by P. falciparum H1-2022 TBD 135 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine#136Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Abbreviations aHUS ALL ALS aBC AD AIH Advanced breast cancer Atopic Dermatitis Autoimmune hepatitis atypical Hemolytic Uremic Syndrome Acute lymphoblastic leukemia Amyotrophic lateral sclerosis IPF JIA LVEF mCRPC MDR MDS AMI Acute myocardial infarction MS AML Acute myeloid leukemia WAMD AS H2H Ankylosing spondylitis head-to-head study versus adalimumab NASH BC Breast cancer nHCM C3G C3 glomerulopathy nr-axSpA CCF Congestive cardiac failure NSCLC CLL CML CRC Chronic lymphocytic leukemia Chronic myeloid leukemia Colorectal cancer PDR PEF PedPsO Pediatric psoriasis COPD Chronic obstructive pulmonary disease PNH COSP Chronic ocular surface pain PsA CRSWNP CSU Severe chronic rhinosinusitis with nasal polyps RCC Chronic spontaneous urticaria PROS CVRR-Lp(a) CVRR-LDLC DME Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) Secondary prevention of cardiovascular events in patients with elevated levels of LDLC Diabetic macular edema RA rMS Idiopathic pulmonary fibrosis Juvenile idiopathic arthritis Left ventricular ejection fraction Metastatic castration-resistant prostate cancer Multi-drug resistant Myelodysplastic syndrome Multiple sclerosis Wet (neovascular) age-related macular degeneration Non-alcoholic steatohepatitis Non-obstructive hypertrophic cardiomyopathy Non-radiographic axial spondyloarthritis Non-small cell lung cancer Proliferative diabetic retinopathy Preserved ejection fraction Paroxysmal nocturnal haemoglobinuria Psoriatic arthritis Renal cell carcinoma PIK3CA related overgrowth spectrum Rheumatoid arthritis Relapsing multiple sclerosis ROP Retinopathy of prematurity DLBCL FL GCA GVHD HCC HD HFPEF HF-REF HNSCC HS ΙΑ IgAN iMN Diffuse large B-cell lymphoma refractory Follicular lymphoma Giant cell arteritis Graft-versus-host disease Hepatocellular carcinoma Huntington's disease Chronic heart failure with preserved ejection fraction Chronic heart failure with reduced ejection fraction Head and neck squamous cell carcinoma Hidradenitis suppurativa Interim analysis IgA nephropathy Membranous nephropathy RP Retinitis pigmentosa RVO Retinal vein occlusion SAA SLE SpA SPMS TNBC T1DM Type 1 Diabetes mellitus SMA Type 1 SMA Type 2/3 Severe aplastic anemia Systemic lupus erythematosus Spinal muscular atrophy (IV formulation) Spinal muscular atrophy (IT formulation) Spondyloarthritis Secondary progressive multiple sclerosis Triple negative breast cancer 136 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine